Investigating the mechanism of ethanol-enhanced GABA release by Kelm, Mary K.
Investigating the Mechanism of Ethanol-enhanced GABA Release 
 
 
 
 
 
Mary Katherine Kelm 
 
 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at 
Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy in the Department of Pharmacology. 
 
 
 
 
 
Chapel Hill 
2009 
 
 
      
 
 
 
 
 
      Approved by: 
 
       Robert Rosenberg, Ph.D. 
 
       Paul Manis, Ph.D. 
 
       Ken McCarthy, Ph.D. 
 
        Hugh Criswell, Ph.D. 
 
       George Breese, Ph.D 
ii 
 
ABSTRACT 
 
MARY KATHERINE KELM: Investigating the Mechanism of Ethanol-enhanced 
GABA Release 
(Under the direction of George Breese) 
 
 
Historically, while research on the actions of ethanol at the GABAergic 
synapse has focused on postsynaptic mechanisms, recent data have 
demonstrated that ethanol also increases both evoked and spontaneous GABA 
release in many brain regions.  However, the mechanism through which ethanol 
acts to enhance GABA release is unknown.  The purpose of this dissertation 
project was to study the mechanism responsible for ethanol-enhanced GABA 
release at the interneuron-Purkinje cell synapse.  First, the ability of ethanol to 
increase GABA release was characterized with whole-cell voltage clamp 
recordings.  Ethanol increased miniature inhibitory postsynaptic current 
frequency and decreased the paired-pulse ratio, which suggests that ethanol 
increases spontaneous and evoked GABA release, respectively.   
I found that calcium release from inositol-1,4,5-trisphosphate receptors 
(IP3Rs) and ryanodine receptors, adenylate cyclase, protein kinase A, 
phospholipase C and protein kinase C all play a role in the ability of ethanol to 
increase spontaneous GABA release, while influx of extracellular calcium into the 
neuron was not involved in this mechanism.  Because of the questionable 
selectively of the IP3R antagonist, electron microscopy was used
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to show that IP3Rs are located in the presynaptic terminals at this synapse.   
Activation of cannabinoid receptors or GABAB receptors inhibited ethanol-
enhanced spontaneous GABA release, but this ethanol mechanism was 
unaffected by tonic activation of these receptors.  It was also determined that 
both protein kinase A and protein kinase C contribute to the generation of 
spontaneous GABA release and cross-talk is not occurring between these two 
intracellular messengers.    
Overall, the large majority of the intracellular messengers investigated 
were involved in ethanol-enhanced GABA release.  This result is not surprising 
considering the promiscuous nature of ethanol and the fact that these 
intracellular messengers can contribute to the generation of spontaneous GABA 
release.  The ability of ethanol to increase GABA release contributes to the 
GABAergic profile of ethanol, and modulation of the GABAergic system 
contributes to alcohol intoxication.  A person who is less sensitive to the 
intoxicating effects of alcohol is prone to developing alcoholism; therefore, 
understanding the molecular mechanisms contributing to alcohol intoxication will  
further our understanding of this disease.                     
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 Chapter I: General Introduction 
 
Alcoholism: the disease 
 Alcoholism is a chronic, progressive disease that drives someone to drink 
regardless of the negative consequences.  The entire body is involved in the 
development of the physical dependence and tolerance associated with chronic 
alcohol use, while the actual development of alcoholism is due to a number of 
neuroadaptations that guide a person towards a relapsing drinking cycle that 
incapacitates their ability to stop drinking.  Obviously a person can drink 
throughout a lifetime and not develop alcoholism.  The difference between this 
group of people and alcoholics is a complex interaction between genetic and 
environmental factors that makes a person more susceptible to developing 
alcoholism (Schuckit, 2009).   
Interestingly, alcohol is the only drug of abuse to have a separate section 
at the National Institutes of Health, the National Institute on Alcohol Abuse and 
Alcoholism.  This is probably due to the fact that the effects of alcoholism on the 
population are widespread: it is estimated that approximately 10% of Americans 
will suffer from alcoholism at some point in their lives, with men more affected 
than women (Grant, 1994).  Excessive alcohol consumption is responsible for 
76,000 deaths annually and is the third leading preventable cause of death 
(Midanik, 2004).  Considering the number of people affected, it is not surprising 
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that the estimated cost placed on society due to alcohol misuse is 185 billion 
dollars yearly (Harwood, 2000).  Most alarming, though, is that alcoholism is 
often left untreated with only roughly 30% of alcoholics receiving treatment 
(Cohen et al., 2007), suggesting that more people are suffering from alcoholism 
than these statistics reflect.  Even when an individual undergoes treatment to 
become abstinent, 45-75% of people relapse at least once in their lifetime 
(Boothby and Doering, 2005).  Therefore, development of more effective 
treatment options is essential if there is going to be an improvement in these 
bleak statistics.   
 
Neuropharmacology of alcoholism and addiction theory 
About 10% of alcoholics receiving treatment use pharmacotherapy to treat their 
disease (Mark et al., 2003).  Because only 30% of alcoholics receive treatment 
(Cohen et al., 2007), approximately 3% of alcoholics are taking advantage of 
available medication.  There are drugs to block craving or reduce alcohol intake, 
induce aversion to alcohol, treat alcohol withdrawal, induce sobriety in intoxicated 
individuals, and, if necessary, treat concomitant psychiatric disorders and/or 
associated drug abuse (Gatch and Lal, 1998).  Unfortunately, there is no “magic 
bullet” to cure alcoholism, which is one of the factors contributing to the low 
prescribing rate (Mark et al., 2003).  Currently there are three medications 
approved by the U.S. Food and Drug Administration for alcoholism: disulfiram 
(Antabuse), acamprosate (Campral), and naltrexone (ReVia, Vivitrol).   
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Disulfiram induces aversion to alcohol by blocking alcohol metabolism.  
Specifically, disulfiram inhibits the aldehyde dehydrogenase enzyme, which 
prevents acetaldehyde from converting to acetate.  Increased acetaldehyde 
levels following alcohol consumption causes adverse physiological effects (ex: 
flushing, chest pain, vomiting, etc.) that deter someone from further alcohol 
drinking (Swift, 1999).  Disulfiram has demonstrated questionable efficacy in 
multiple clinical trials but is more effective in treatment programs that involve 
monitoring medicine consumption (Garbutt, 2009).  Naltrexone and acamprosate 
are different from disulfiram in that they target the neurobiological processes 
thought to be involved in the development of alcoholism.  Naltrexone, an opioid 
receptor antagonist, reduces alcohol intake and craving by blocking the 
rewarding effects of alcohol (Volpicelli et al., 1995).  Acamprosate normalizes 
glutamatergic neurotransmission, which is one of the many neurotransmitter 
systems that is dysregulated during chronic alcohol use, but the exact 
mechanism is unknown (Heilig and Egli, 2006).  One study suggests that 
acamprosate acts as a glutamate stabilizer specifically during alcohol withdrawal, 
(Mann et al., 2008), thereby preventing withdrawal from becoming a motivating 
factor to drink again.  
 Even these drugs are limited- in a clinical trial testing the effectiveness of 
treatment options for alcoholics, a combination of naltrexone and acamprosate 
had a comparable effect to intense behavioral therapy (Anton et al., 2006).  While 
the most successful treatment of alcoholism might require both pharmacological 
and psychological treatment, there is obviously still room for improvement 
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regarding the pharmacotherapy options.  Advances in this field will require a 
better understanding of the cellular and molecular effects of alcohol, which have 
been quite difficult to study due to the promiscuous effects of alcohol on multiple 
neurobiological pathways and the multiple stages involved in the development of 
alcoholism. 
There are three stages to addiction: preoccupation/anticipation (i.e. 
craving), binge intoxication, and withdrawal.   These stages are interconnected 
and feed off of each other, contributing to a cycle that gets more intense over 
time, which can eventually lead to addiction (Koob and Le Moal, 1997).  The 
desire to drink comes from both positive and negative reinforcing effects (Koob 
and Le Moal, 1997).  Positive reinforcing effects involve feeling aroused/tense 
before taking a drink and euphoric during the act of drinking.  Negative 
reinforcing effects involve feeling anxious/stressed before taking a drink and 
relieved during the act of drinking.   During the addiction cycle, the positive 
reinforcing effects become less motivating and the negative reinforcing effects 
predominate.  Because addiction is a complex disease, there are a number of 
neuropeptide and neurotransmitter systems that are affected either directly or 
indirectly by alcohol. 
 
The role of stress-related peptides in the development of alcoholism   
Neuropeptide Y (NPY) and corticotropin-releasing factor (CRF) are 
neuropeptides that play opposite roles in regulating anxiety: NPY is anxiolytic 
while CRF is anxiogenic (Valdez and Koob, 2004; Heilig and Egli, 2006).  NPY 
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null mice consume more alcohol and are less sensitive to the sedative/hypnotic 
effects of alcohol compared to wild-type controls (Thiele et al., 1998).  In 
accordance with these data, transgenic mice that overexpress NPY consume 
less alcohol and are more sensitive to the sedative/hypnotic effects of alcohol 
(Thiele et al., 1998).  A number of studies have confirmed these results (for 
review see Heilig and Egli, 2006).  These data suggest that NPY contributes to 
the rewarding/intoxicating effects of alcohol.  
In contrast to NPY, CRF contributes to the anxiety experienced during 
alcohol withdrawal, which is a negative reinforcing effect for future alcohol 
consumption.  Because a CRF type 1 (CRF1) receptor antagonist blocks the 
anxiety/stress response, the CRF1 receptor is thought to mediate the CRF 
effects linked to stress and anxiety (Britton et al., 1986).  Administration of a 
CRF1 receptor antagonist decreases alcohol withdrawal-induced anxiety 
(Rassnick et al., 1993b; Breese et al., 2004; Knapp et al., 2004; Overstreet et al., 
2004), and alcohol withdrawal increases levels of CRF in the amygdala (Merlo 
Pich et al., 1995).  A CRF1 receptor antagonist reduces alcohol intake in alcohol-
dependent animals, but has no effect in nondependent animals (Sabino et al., 
2006).  It is hypothesized that during alcohol intoxication CRF levels decrease 
and NPY levels increase and return to baseline levels afterwards.  After a period 
of chronic alcohol abuse, CRF and NPY do not return to baseline levels.   This 
“altered baseline” is one of the neuroadaptations that can contribute to a person’s 
inability to stop drinking as they attempt to “fix” this imbalance with more alcohol 
consumption (Valdez and Koob, 2004).   
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The reward pathway and the development of alcoholism 
The mesolimbic pathway, or “reward pathway” involves dopamine neurons 
originating in the ventral tegmental area (VTA) releasing dopamine into the 
nucleus accumbens in response to rewarding experiences (Wise, 1998).  Alcohol 
increases dopamine release in the nucleus accumbens (Imperato and Di Chiara, 
1986), and certain acute behavioral effects of alcohol are attenuated in the 
presence of a dopamine receptor antagonist (Liljequist et al., 1981; Risinger et 
al., 1992).  There is a direct relationship between the amount of dopamine 
signaling in the mesolimbic pathway and the amount of alcohol consumption 
(Hodge et al., 1997; Cohen et al., 1998; Gonzales et al., 2004; Rodd et al., 
2008).  During alcohol withdrawal, the functionality of this dopaminergic system is 
reduced, which could contribute to relapse because the alcoholic is trying to 
“overcome” the low dopamine state (Diana et al., 1993; Weiss et al., 1996; Shen 
et al., 2007; Volkow et al., 2007).   
Desensitization of the mesolimbic dopamine system and its related 
behaviors is thought to be a critical component of the development of drug 
addiction (Robinson and Berridge, 1993).  However, while behavioral 
sensitization to psychostimulants and opiates involves sensitization of drug-
evoked dopamine levels, this is not the case for development of alcohol 
behavioral sensitization (Zapata et al., 2006).  Therefore, while dopamine has a 
role in the development of alcoholism, caution must be taken when attempting to 
group alcoholism into drug addiction in general.   
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Opioids are widely known as the neuropeptides that lead to a “feel good” 
response once they bind to three potential opioid receptors; moreover, opioid 
receptor agonists are used in pain management, such as morphine (McQuay, 
1989).  In addition to pain management, the opioid system plays a role in reward 
and reinforcement through activation of mu- and delta- opioid receptors that 
increase dopamine release in the mesolimbic pathway (Spanagel et al., 1990).  
Naltrexone, one of the three drugs approved for the treatment of alcoholism, is a 
nonspecific competitive opioid receptor antagonist that inhibits the reward felt 
from drinking alcohol, thereby reducing the amount of alcohol consumed 
(Volpicelli et al., 1995).  Naltrexone can reverse the alcohol-induced increase in 
dopamine signaling in the mesolimbic pathway, suggesting that opioids are a 
mediator in the alcohol-dopamine interaction (Benjamin et al., 1993).  Alcohol 
increases opioid neurotransmission (Gianoulakis, 2001), which could in turn 
increase dopamine neurotransmission, leading to the rewarding properties of 
alcohol consumption.  Data suggest that opioids do not affect the VTA dopamine 
neurons directly, but instead hyperpolarize the GABAergic interneurons (i.e. 
disinhibition) that provide inhibitory signals to the dopamine VTA neurons 
(Johnson and North, 1992).  Overall, these data suggest that the opioid and 
dopamine systems play an important role in the rewarding effects (i.e. positive 
reinforcing effects) associated with alcohol consumption. 
 
Glutamate neurotransmission and the development of alcoholism   
Glutamate, the major excitatory neurotransmitter in the brain, can activate 
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both metabotropic glutamate receptors (mGluRs) and ionotropic glutamate 
receptors (Ozawa et al., 1998).  There are three ionotropic glutamate receptors: 
N-methyl-D-aspartic acid (NMDA) receptors, alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors and kainate receptors, which are all 
affected by alcohol.  At physiologically relevant concentrations, ethanol inhibits 
kainate receptor-mediated excitatory neurotransmission (Weiner et al., 1999; 
Carta et al., 2003; Lack et al., 2008).  Because activation of kainate receptors 
causes an anxiety response, the anxiolytic properties of acute alcohol exposure 
could be mediated through inhibition of kainate receptors (Lack et al., 2008).  
Ethanol also inhibits AMPA receptors (Martin et al., 1995; Wang et al., 1999; 
Frye and Fincher, 2000; Wirkner et al., 2000; Jones et al., 2008).  At the 
behavioral level, increasing AMPA receptor-mediated neurotransmission can 
reverse some of the acute alcohol effects in the rat (Jones et al., 2008).  
Additionally, AMPA receptor-mediated neurotransmission contributes to alcohol-
seeking behavior and relapse (Sanchis-Segura et al., 2006). 
The interaction between alcohol and NMDA receptors has been more 
extensively studied.  Like the other ionotropic receptors, acute ethanol inhibits 
NMDA receptors, and different NMDA receptor subunit combinations have 
different sensitivities to ethanol (for review see Allgaier, 2002).  Behaviorally, 
NMDA receptors have been implicated in alcohol withdrawal, craving, relapse, 
tolerance and dependence (Khanna et al., 1993; Riaz and Faingold, 1994; Ripley 
and Little, 1995; Holter et al., 2000; Ron, 2004).  Chronic alcohol exposure 
results in an upregulation of NMDA receptors, which is consistent with alcohol 
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withdrawal-induced hyperactivation of the glutamate system (Spanagel and 
Zieglgansberger, 1997).  Despite this role for ionotropic glutamate receptors in 
alcohol related behaviors, developing pharmacotherapies specifically targeting 
these sites is problematic due to the essential role these receptors play in brain 
functioning and their ubiquitous expression throughout the brain (Heilig and Egli, 
2006). 
The mGluRs offer a unique advantage over the ionotropic glutamate 
receptors because of differences in presynaptic versus postsynaptic localization 
of the different mGluR subtypes (Heilig and Egli, 2006).  There are eight different 
mGluR subtypes, which are divided into three groups: group 1 (mGluR1, 
mGluR5), group 2 (mGluR2, mGluR3), and group 3 (mGluR4, mGluR6, mGluR7 
and mGluR8).  The group 1 mGluRs are primarily located postsynaptically, while 
group 2 and 3 mGluRs are primarily located presynaptically (Raiteri, 2008).  A 
mGluR5 antagonist reduces alcohol drinking and craving in animal studies 
(Backstrom et al., 2004; Cowen et al., 2005; Schroeder et al., 2005; Hodge et al., 
2006), possibly through a reduction in the subjective effects of alcohol (Besheer 
and Hodge, 2005).  On the molecular level, a mGluR5 antagonist reduces 
glutamatergic signaling through NMDA receptors by preventing PKC 
phosphorylation of the NMDA receptor (Hermans and Challiss, 2001; Kotecha et 
al., 2003); moreover, this could be the mechanism responsible for the 
effectiveness of the mGluR5 antagonist on reducing alcohol consumption (Heilig 
and Egli, 2006).  While the majority of studies have investigated the mGluR5s, an 
agonist at the group 2 mGluRs reduces excessive alcohol drinking and craving in 
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alcohol preferring rats (McKinzie et al., 2005).  This agonist reduces anxiety and 
stress in preclinical and clinical studies, which offers one potential mechanism for 
the reduced alcohol drinking (Marek, 2004).  Overall, the mGluRs are a 
promising target for the development of new pharmacotherapies to treat 
alcoholism. 
 
GABA neurotransmission and the development of alcoholism 
Gamma-aminobutyric Acid (GABA) is the most abundant inhibitory 
neurotransmitter in the brain and can bind to two ionotropic GABA receptors 
(GABAA and GABAC) and one metabotropic GABA receptor (GABAB).  GABAB 
receptors are G protein-coupled receptors (GPCRs) that are located at both 
presynaptic and postsynaptic sites (Raiteri, 2008).  The presynaptic GABAB 
receptors are negative autoreceptors that decrease GABA release from the 
presynaptic terminal upon GABA binding to the GABAB receptor (Raiteri, 2008).  
Baclofen, a GABAB receptor agonist, suppresses alcohol drinking in alcohol 
naïve rats and alcohol dependent rats (Daoust et al., 1987; Colombo et al., 2000; 
Colombo et al., 2002; Anstrom et al., 2003; Colombo et al., 2003a; Janak and 
Michael Gill, 2003).  It also suppresses the motivational properties of alcohol 
(Colombo et al., 2003b; Maccioni et al., 2005), the development of tolerance to 
behavioral effects (Cott et al., 1976; Zaleski et al., 2001), and alcohol withdrawal 
symptoms (Colombo et al., 2000; Knapp et al., 2007).  In clinical trials baclofen 
promotes alcohol abstinence, prevents alcohol relapse and reduces alcohol 
withdrawal in alcoholics (Addolorato et al., 2006).  It is also effective in alcoholics 
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with cirrhosis of the liver, which is caused by extensive alcohol use (Addolorato 
et al., 2007).  The current drugs used to treat alcoholism undergo extensive liver 
metabolism, rendering them useless in severe alcoholics with cirrhosis of the 
liver.  Therefore, baclofen could potentially offer an untreated population of 
alcoholics a pharmacotherapy option.     
At the GABAergic synapse, GABA is released from the presynaptic 
GABAergic neuron and binds to GABA binding sites on the postsynaptic 
ionotropic GABA receptors.  The GABAA and GABAC receptors have a 
pentameric structure, with the five subunits coming together to form a chloride 
channel that allows chloride to flow into the neuron after GABA binding, which 
results in hyperpolarization of the neuron (Baumann et al., 2001).    There are 
many types of subunits that can contribute to the formation of the ionotropic 
GABA receptors: α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-3.  While the number of 
possible GABA subunit combinations is enormous, only a small number of 
combinations have been found in brain (McKernan and Whiting, 1996).  The 
GABAC receptors contain one or more ρ subunits and are only found in retina, 
thalamus, hippocampus, pituitary and gut (Chebib, 2004). The interaction 
between GABAC receptors and alcohol has not been thoroughly studied, but 
there is one study suggesting that ethanol potentiates the response of GABAC 
receptors (Yeh and Kolb, 1997).  The most common GABA receptor in the brain 
is the GABAA receptor, with the majority of GABAA receptors consisting of two α 
subunits, two β subunits and one γ subunit (Farrar et al., 1999).  In addition to 
GABA, there are binding sites on the GABAA receptor for benzodiazepines, 
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barbiturates and neurosteroids (Mohler and Okada, 1977; Briley and Langer, 
1978; Majewska et al., 1986).   
There are a number of behavioral studies suggesting there is an 
interaction between alcohol and the GABAA receptor.  Specifically, the effects of 
alcohol on motor function (Frye et al., 1980; Frye and Breese, 1982; Liljequist 
and Engel, 1982), sleep time (Liljequist and Engel, 1982; Givens and Breese, 
1990), temperature (Liljequist and Engel, 1982), convulsions (Liljequist and 
Engel, 1982), anxiety (Frye et al., 1980) and learning and memory (White et al., 
1997) were similar to those seen with drugs that act directly on the GABAA 
receptor, the benzodiazepines and barbiturates (Mohler and Okada, 1977; Briley 
and Langer, 1978).  Additionally, benzodiazepines and barbiturates enhance the 
alcohol effect on motor impairment (Martz et al., 1983).  Consistent with these 
data, GABAA receptor antagonists and a benzodiazepine inverse agonist block 
the behavioral effects of alcohol (Liljequist and Engel, 1984; Koob et al., 1986; 
Suzdak et al., 1986a; Koob et al., 1988; Ticku and Kulkarni, 1988; McCown and 
Breese, 1989) and reduce alcohol consumption (Rassnick et al., 1993a; Petry, 
1995).  Benzodiazepines and barbiturates substitute for alcohol in drug 
discrimination studies, suggesting that the drugs have similar subjective effects 
(Grant et al., 2000; Shannon et al., 2004).  Additionally, GABA agonists, 
benzodiazepines and barbiturates can attenuate some of the negative effects 
associated with alcohol withdrawal (Cooper et al., 1979; Frye et al., 1983; 
McCown et al., 1986; Criswell and Breese, 1989).  
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Overall, these data provide evidence from pre-clinical and clinical studies 
that alcohol affects GABAergic neurotransmission at multiple sites to manifest 
certain behaviors. To complement the behavioral data, there is evidence that 
ethanol affects GABAergic neuronal activity, which occurs in a brain region-
specific manner (Nestoros, 1980; Mereu and Gessa, 1985; Bloom and Siggins, 
1987; Givens and Breese, 1990; Simson et al., 1991; Criswell et al., 1993; 
Criswell et al., 1995).  The ability of ethanol to alter GABAergic 
neurotransmission in a brain region-specific manner is consistent with alcohol-
induced behaviors that are linked to certain brain regions (McCown et al. 1986).  
Therefore, the GABAergic synapse has the potential to be a useful target when 
developing new treatment options.  The effects of ethanol at the GABAergic 
synapse on the cellular and molecular level will be discussed in more detail 
below. 
  
Ethanol and postsynaptic GABAA receptor interactions 
As described above, ethanol has similar behavioral effects to the 
benzodiazepines and barbiturates, which bind to postsynaptic GABAA receptors.  
Therefore, the initial hypothesis was that ethanol binds directly to GABAA 
receptors.  This idea was supported by a number of studies that found ethanol 
enhances GABA-induced Cl- currents (Ticku et al., 1983; Suzdak et al., 1986b; 
Aguayo, 1990; Allan et al., 1991; Reynolds et al., 1992; Sigel et al., 1993; Harris 
et al., 1995; Mori et al., 2000); however, these results were not always 
reproducible (Siggins et al., 1987; Palmer and Hoffer, 1990; White et al., 1990; 
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Frye et al., 1994; Marszalec et al., 1998; Peoples and Weight, 1999; Ming et al., 
2001).  One possible explanation for these inconsistent results is differences in 
the various preparations used, which includes cell lines, oocytes, and primary 
neuronal cultures (Siggins et al., 2005; Lovinger and Homanics, 2007).   
Another explanation is that ethanol interacts with select GABAA receptor 
subunits.  This hypothesis is supported by data showing that ethanol affects 
GABA-mediated neuronal activity and alcohol-related behaviors in a brain region-
specific manner (see above).  Additionally, experiments investigating the effect of 
ethanol on GABAA receptor-mediated synaptic currents in the slice have seen a 
brain region-specific effect (Carlen et al., 1982; Siggins et al., 1987; Proctor et 
al., 1992; Weiner et al., 1994; Wan et al., 1996; Ariwodola and Weiner, 2004; Nie 
et al., 2004).  Therefore, it was proposed that GABAA receptor subunit 
composition dictates the effectiveness of ethanol at a GABAA receptor and 
contributes to the brain region-specific ethanol effects.  The most abundant 
GABAA receptor in the brain is the 2α12β2γ2 GABAA receptor, and zolpidem is a 
selective agonist at α1-containing GABAA receptors (McKernan and Whiting, 
1996).  Early work supported that the effect of zolpidem on a GABAA receptor 
could predict the effect of ethanol on that GABAA receptor, implying that ethanol 
selectively acts at α1-containing GABAA receptors (Criswell et al., 1993; Criswell 
et al., 1995); however, later work disproved this hypothesis (Criswell et al., 2003).  
Despite this setback, focus still remained on ethanol interacting with specific 
GABAA receptor subunits, but the focus shifted to extrasynaptic GABAA 
receptors. 
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Ethanol and extrasynaptic GABAA receptor interactions 
Extrasynaptic GABAA receptors are located outside of the GABAergic 
synapse and exhibit different properties than synaptic GABAA receptors.  
Extrasynaptic GABAA receptors can be activated from the reversal of GABA 
transporters, GABA release from astrocytes, and GABA spillover from 
presynaptic GABA release (for review see Glykys and Mody, 2007).  Synaptic 
GABAA receptors respond to high concentrations of GABA (in the mM range) and 
are activated for only a few milliseconds.  This “phasic conductance” of synaptic 
GABAA receptors is in contrast to the “tonic conductance” of extrasynaptic 
GABAA receptors, which are sensitive to lower concentrations of GABA and 
remain activated for a longer period of time (Saxena and Macdonald, 1994; 
Mody, 2001).  Consequently, since GABA is almost always present in the 
extracellular space, most extrasynaptic GABAA receptors are continuously 
activated (Glykys and Mody, 2007; Lovinger and Homanics, 2007).  This tonic 
conductance is seen in the cerebellum, cortex, hippocampus, thalamus and 
spinal cord, which are areas that are also sensitive to ethanol (Glykys and Mody, 
2007).   
Extrasynaptic GABAA receptors are more sensitive to the effects of 
ethanol compared to the synaptic GABAA receptors. Studies in oocytes found 
that ethanol acts at GABAA receptors containing δ and β3 subunits associated 
with α4 or α6 subunits at concentrations as low as 1 mM (Sundstrom-Poromaa et 
al., 2002; Wallner et al., 2003), which was confirmed in the slice (Wei et al., 
2004; Hanchar et al., 2005; Glykys et al., 2007).  However, studies in another 
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laboratory attempting to replicate the oocyte studies have been unsuccessful 
(Borghese et al., 2006).  Interestingly, ethanol-induced GABA release onto 
cerebellar granule neurons is proposed to activate a tonic current mediated by 
α6βxδ GABAA receptors via GABA spillover, which suggests that at least in one 
brain region ethanol can affect extrasynaptic GABAA receptors indirectly (Carta et 
al., 2004).  Site-directed mutagenesis studies using this same subunit 
combination concluded that ethanol directly affects the α6βxδ GABAA receptors 
(Hanchar et al., 2005), but this result could not be reproduced (Botta et al., 
2007).  Therefore, while the majority of evidence supports there being an 
ethanol-extrasynaptic GABAA receptor interaction, more studies are necessary to 
determine the mechanism.  Overall, while ethanol most likely interacts with 
GABAA receptors in a subunit-specific manner, the GABAergic profile of ethanol 
is more convoluted than previously thought (Weiner and Valenzuela, 2006).  
 
The tipsy terminal: ethanol actions at the GABA terminal 
In the presynaptic terminal, GABA is synthesized from glutamate by 
glutamate decarboxylase and loaded into the synaptic vesicles through a 
vesicular GABA transporter (Martin, 1993; McIntire et al., 1997; Sagne et al., 
1997). The vesicles dock at the plasma membrane and are primed for vesicle 
fusion.  Once the vesicles fuse with the membrane, GABA is released from the 
presynaptic terminal into the synaptic cleft and binds to the postsynaptic GABAA 
receptors (Sudhof, 1995).  GABA transporters located on the presynaptic 
GABAergic neurons as well as surrounding astrocytes remove GABA from the 
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synaptic cleft and extracellular space.  At this point GABA is inactivated by 
GABA-transaminase or is recycled as a neurotransmitter (Madsen et al., 2008). 
GABA was not recognized as a neurotransmitter until the late sixties 
(Otsuka et al., 1966; Roberts and Kuriyama, 1968), and around this same time 
data surfaced showing that ethanol changes the concentration of GABA in the 
brain (Gordon, 1967).  However, because researchers within the alcohol field 
were focused on the direct effects of ethanol on the GABAA receptor, there were 
no studies investigating the potential presynaptic effects of ethanol.  Many years 
later, intracellular recordings were used to study the GABAergic effect of ethanol.  
Carlen et al. (1982) found that ethanol enhances evoked inhibitory postsynaptic 
currents (eIPSCs) in the hippocampus, and while analysis of eIPSCs cannot 
indicate whether a presynaptic or postsynaptic GABAergic effect was responsible 
for the change, the authors postulated that the eIPSC enhancement was 
mediated by a presynaptic effect of ethanol. 
However, a few years later a study found that ethanol inhibits eIPSCs at 
this same synapse (Siggins et al., 1987).  Additionally, Siggins and colleagues 
had data suggesting that the change in eIPSC amplitude was primarily due to a 
presynaptic mechanism.  However, they concluded that ethanol was decreasing 
GABA release, which was consistent with biochemical studies showing that 
ethanol decreases GABA release in cortical regions (Carmichael and Israel, 
1975; Howerton and Collins, 1984; Strong and Wood, 1984).  Similar studies 
investigating the effect of ethanol on eIPSCs in the hippocampus continued to 
report inconsistencies (Proctor et al., 1992; Weiner et al., 1994), which led to the 
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Siggins group repeating this study (Wan et al., 1996).  The new study used 
glutamate antagonists because of a potential source of glutamate 
neurotransmission in their preparation (Davies and Collingridge, 1989), and this 
time they found no ethanol effect on eIPSC amplitude.  However, in the presence 
of a GABAB receptor antagonist, ethanol consistently increased eIPSC amplitude 
(Wan et al., 1996).  The Siggins group postulated again that the change in eIPSC 
amplitude was due a presynaptic effect, but they discounted this possibility 
because their new data was consistent with ethanol increasing GABA release, 
which was not in agreement with the biochemical data (Carmichael and Israel, 
1975; Howerton and Collins, 1984; Strong and Wood, 1984).  However, studies 
in the nucleus accumbens slice provided additional evidence for ethanol having 
presynaptic GABAergic effects, and as a result, the Siggins group came back to 
the hypothesis that ethanol acts presynaptically to increase GABA release (see 
Siggins et al., 2005).   
In response to these findings, Dr. Dennis Twombly organized a National 
Institute on Alcohol Abuse and Alcoholism workshop in 2002 to discuss the 
deficiency in studies exploring the presynaptic effects of ethanol (Roberto et al., 
2006).  Shortly thereafter, a number of studies came out supporting the idea that 
ethanol increases GABA release.  An injection of ethanol into mice one day 
before electrophysiology recordings caused an increase in GABA release in the 
VTA (Melis et al., 2002).  The Siggins group published a study showing that 
ethanol increases both spontaneous and evoked GABA release in the central 
nucleus of the amygdala (Roberto et al., 2003).  Two studies came out 
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simultaneously showing that ethanol increases GABA release in motor neurons, 
with one of the papers showing that ethanol actually inhibited postsynaptic 
GABAA receptors (Sebe et al., 2003; Ziskind-Conhaim et al., 2003).   
Currently, ethanol has been shown to increase GABA release in the 
following brain regions: central nucleus of the amygdala (Roberto et al., 2003; 
Nie et al., 2004), basolateral amygdala (Zhu and Lovinger, 2006), hippocampus 
(Ariwodola and Weiner, 2004; Sanna et al., 2004; Li et al., 2006), VTA (Melis et 
al. 2002, Theile et al. 2008), cerebellum (Carta et al., 2004; Ming et al., 2006; 
Criswell et al., 2008) and brainstem/spinal cord (Sebe et al., 2003; Ziskind-
Conhaim et al., 2003).  Ethanol has no effect on GABA release in the cortex, 
thalamus, and lateral septum, which is consistent with the brain region-specific 
effects of ethanol on GABA neurotransmission in vivo (Criswell et al., 2008; Jia et 
al., 2008; Mameli et al., 2008).  Due to the novelty of the concept that ethanol 
acts presynaptically, the mechanism through which ethanol acts to increase 
GABA release has yet to be elucidated.  The focus of this dissertation is to 
determine the mechanism responsible for ethanol-enhanced GABA release.      
 
Description of model system: interneuron-Purkinje cell synapse 
Multiple studies have shown that ethanol exposure impairs the 
development of the cerebellum and causes volume loss in a developed 
cerebellum (Bauer-Moffett and Altman, 1977; Servais et al., 2007).  The 
cerebellum plays a role in controlling coordination, sensory perception, motor 
control, motor learning and reflex adaptation (Robinson, 1976; McCormick and 
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Thompson, 1984; Baillieux et al., 2008); these cerebellar functions are consistent 
with the acute effects of alcohol involving alterations in balance, speech, and 
motor coordination.  Ethanol depresses GABAA receptor-mediated Purkinje cell 
firing (Siggins and French, 1979; Sorensen et al., 1980; George and Chu, 1984), 
which is consistent with ethanol increasing the amount of GABA released from 
the interneurons (i.e. stellate/basket cells) onto the Purkinje cells (Ming et al., 
2006; Criswell et al., 2008; Mameli et al., 2008).   
The cerebellum has four main types of neurons: Purkinje cells, granule 
cells, stellate/basket cells, and Golgi cells (Voogd and Glickstein, 1998; see Fig. 
1.1).  The Purkinje cells are large, GABAergic neurons that project solely to the 
deep cerebellar nuclei.  Purkinje cells are oriented in a single row, which serves 
as the border between the molecular cell layer and the granule cell layer.  In 
addition to the Purkinje cell dendritic trees, the molecular layer houses the 
stellate and basket cells, both of which are GABAergic and provide inhibitory 
input to the Purkinje cells.  The basket cells synapse around the Purkinje cell 
soma and main dendrites, while the stellate cells synapse with more distal 
dendrites (Vincent et al., 1992). 
  The other inhibitory interneurons in the cerebellum are the Golgi cells, 
which synapse onto the granule cells.  Granule cells are small glutamatergic 
neurons that are abundantly expressed throughout the granule cell layer.  The 
granule cell axons (i.e. parallel fibers) ascend to the molecular cell layer and 
synapse onto Purkinje cell spines.  The Golgi cells receive input from the parallel 
fibers and provide inhibitory feedback to the granule cells.  The granule cells 
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receive excitatory input from the mossy fibers, and the Golgi cells act as a filter at 
this synapse.  Climbing fibers, which originate from the inferior olive, are 
excitatory and synapse onto the Purkinje cells. 
For these experiments no distinction was made between the basket cells 
and stellate cells.  One difference between the two cell types is expression of 
parvalbumin, which is absent in stellate cells up to postnatal day 12 but present 
in basket cells throughout development (Collin et al., 2005a).  Because 
parvalbumin plays a role in presynaptic calcium signaling, these experiments do 
not use rats under postnatal day 12.  Otherwise, the basket and stellate cells 
have very similar characteristics (Sultan and Bower, 1998). 
 
Ethanol-enhanced spontaneous GABA release and intracellular 
messengers 
Previous studies investigating ethanol-enhanced GABA release have 
focused on GPCRs, specifically the GABAB receptor, δ opioid receptor, 
nociceptin/orphanin FQ peptide receptor, and the CRF1 receptor (Wan et al., 
1996; Ariwodola and Weiner, 2004; Nie et al., 2004; Roberto and Siggins, 2006; 
Kang-Park et al., 2007).  The following work will focus on the signal transduction 
mechanisms that are downstream of the GPCRs.  When GPCRs are activated by 
an external stimulus, there is a conformational change in the receptor that 
causes an allosteric change in the nearby G protein.   The Gα subunit substitutes 
guanosine 5'-diphosphate for guanosine-5'-triphosphate and dissociates from the 
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βγ subunit, freeing both the Gα subunit and the βγ subunit to interact with their 
respective downstream messengers (for review see Hepler and Gilman, 1992).   
These experiments will place focus on the signal transduction pathways 
affected by 3 G protein subunits: Gαi, Gαs, and Gαq.  The Gαi- and Gαs-linked 
pathways affect (in opposite directions) levels of adenylate cyclase and protein 
kinase A (Hanoune and Defer, 2001), while the Gαq–linked pathway activates 
phospholipase C and leads to calcium release from the internal stores and 
activation of protein kinase C (Rhee, 2001).  The purpose of the following studies 
was to determine if these intracellular messengers are playing a role in the ability 
of ethanol to increase spontaneous GABA release at the interneuron-Purkinje 
cell synapse.   
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Figure 1.1.  Cerebellum circuitry.  This diagram includes the circuitry discussed in 
the text and does not depict all synapses in the cerebellum.  Excitatory 
neurotransmission is represented by red, inhibitory neurotransmission is 
represented by blue, and a mixture of both is represented by purple.  MF: mossy 
fiber; DCN: deep cerebellar nuclei; IO: inferior olive; CF: climbing fiber; GC: 
granule cell; PF: parallel fiber; PC: Purkinje cell; GgC: Golgi cell; SC: stellate cell; 
BC: basket cell. Adapted from: http://en.wikipedia.org/wiki/Cerebellum.  
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Chapter II: General Methods 
 
Slice preparation for electrophysiology.  Sprague-Dawley rats, 13-20 days 
old, were anesthetized with an intraperitoneal injection of 75% urethane (Sigma, 
St. Louis, MO) and decapitated after disappearance of the plantar reflex.  The 
brain was rapidly removed and placed in a 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES) buffered solution of the following composition (in 
mM): 145 NaCl, 5 KCl, 10 HEPES, 2 CaCl2, 1 MgCl2, 10 glucose and 5 sucrose 
(pH to 7.4 with NaOH).  The cerebella were isolated and parasagittal slices, 350 
µm thick, were cut with a vibrating microtome (Leica VT1000S, Vashaw 
Scientific, Norcross, GA) in a low sodium solution of the following composition (in 
mM): 112.5 sucrose, 63 NaCl, 3 KCl, 1.25 NaH2PO4, 24 NaHCO3, 6 MgSO4, 0.5 
CaCl2, 10 glucose, and gassed with 95% O2/5% CO2.  The slices were placed in 
a chamber containing oxygenated artificial cerebrospinal fluid (ACSF) of the 
following composition (in mM): 124 NaCl, 3.25 KCl, 1.25 KH2PO4, 10 glucose, 2 
MgSO4, 20 NaHCO3, 2 CaCl2, and gassed with 95% O2/5% CO2.  The slices 
were equilibrated at least one hour at room temperature before starting 
experiments.   
 
Whole-cell voltage clamp recordings.  A slice was placed at the bottom of a 
chamber that was attached to the stage of a microscope (BX5OWI, Olympus, 
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Japan) and was perfused with oxygenated ACSF (21-24°C)  at a flow rate of 0.5 
ml/min.  The cells were visualized using infrared illumination under differential 
interference contrast optics with a 40X LUMPlanFl water-immersion objective 
(Olympus) and displayed on a monitor via a video camera (C2400, Hamamatsu, 
Japan).  Recording electrodes were pulled from borosilicate glass (Drummond 
Scientific Company, Broomall, PA) and had a resistance of 2.5-3 MΩ when filled 
with internal solution.  The composition of the internal solution was the following 
(in mM):150 KCl, 3.1 MgCl2, 15 HEPES, 5 K-ATP, 5 EGTA, 15 phosphocreatine.  
The internal solution pH was adjusted to 7.4 with KOH and the osmolarity was 
approximately 310 mOsms.   For the 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-
tetraacetic acid (BAPTA) experiments, the composition of the internal solution 
was the following (in mM):105 KCl, 3.1 MgCl2, 15 HEPES, 5 K-ATP, 30 BAPTA 
tetrapotassium salt, 15 phosphocreatine (pH to 7.4 with KOH).   For the paired-
pulse studies, 5 mM N-(2,6-Dimethylphenylcarbamoylmethyl) triethylammonium 
bromide (QX-314) was added to the internal solution to block the generation of 
action potentials. 
  Data were displayed on an oscilloscope (V-212, Hitachi, Japan), digitized 
at 5 kHz, and stored on a personal computer.  The membrane potential was held 
at -70 mV using a patch-clamp amplifier (Axopatch 200B, Axon Instruments, 
Union City, CA), and data were collected with Clampex 8.1 software (Axon 
Instruments).  The capacitance and access resistance were monitored 
continuously throughout the recordings and a change of 10% or more was 
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sufficient to exclude the recording from analysis.  Only one protocol/recording 
was conducted per slice to avoid contamination.   
 
Drug preparation and drug delivery system.  Each drug was made up as a 
concentrated stock solution, which was diluted in aCSF and inserted into sealed 
syringes on the day of use.  CNQX (10 µM) and AP5 (50 µM) were added to all 
solutions inserted into the sealed syringes.  Table 2.1 includes a description of 
each drug, the supplier, the stock solution concentration and the storage 
conditions.  The final concentration of dimethyl sulfoxide (DMSO) used in the 
experiments was less that 0.1%, which does not alter the miniature inhibitory 
postsynaptic current (mIPSC) properties (n = 4, data not shown).  When BAPTA-
AM, SQ 22,536, DDA, edelfosine, bafilomycin A1 and H-89 were used in an 
experiment, there was a 30 minute to 2 hour drug pre-incubation period with the 
slice before starting the experiment.  Each sealed syringe was attached to Teflon 
tubing that was connected to a multi-barrel perfusion pencil (Automate Scientific, 
Inc.; Sarasota, FL; 250 µm tip diameter), which was positioned 150-250 µm from 
the cell being tested.   
 
Protocol and analysis for paired-pulse experiments.  Platinum-iridium 
stimulating electrodes were lowered into the molecular layer approximately 150 
µm from the experimental Purkinje cell. The membrane of the cell was ruptured, 
and the control solution was delivered through the multi-barrel perfusion pencil.  
After allowing the cell to stabilize, two stimuli were delivered (0.2 ms duration and 
27 
 
50 ms inter-stimulus interval) at 0.1 Hz, which generated a paired-pulse (PP) 
record of two closely spaced evoked inhibitory postsynaptic currents (eIPSCs).  A 
maximum stimulation was applied to determine the maximum current response.  
The stimulus strength was reduced to a level that generated half the maximum 
current response, and this stimulus strength was used for the experiment.  
Following a minimum of 6 PP records obtained at 10 sec intervals for the pre-
control value, the ethanol solution was delivered through the multi-barrel 
perfusion pencil and 5 minutes later a second series of PP records was collected.  
Ethanol was washed out for at least 5 minutes and a final series of PP records 
was collected.  The miniAnalysis software (version 5.6.4; Synaptosoft, Decatur, 
GA) was used to generate averaged PP traces from the PP records collected for 
each cell. The averaged PP trace was used to calculate the paired-pulse ratio 
(PPR), which is the ratio of the second eIPSC amplitude to the first 
(eIPSC2/eIPSC1). The PPR value for each cell in a given group (pre-control, 
ethanol, washout) were averaged together and represented as the mean ± 
standard error of the mean (SEM).  The “averaged control” values were 
calculated from the pre-control and washout ((pre-control + washout)/2).        
 
Mechanically dissociated neuron preparation.  A slice was transferred to a 
recording chamber containing the HEPES-buffered solution.  A 0.3 mm probe 
touched the surface of the cell layer of the submerged slice and was vibrated 
(~0.2 mm amplitude at 10 Hz) for 3 minutes.  When the resulting mechanical 
forces break a neuron free from the matrix, most of the dendritic tree is sheared 
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off as well as the distal parts of axon; however, the presynaptic terminals remain 
attached to the soma (Akaike and Moorhouse, 2003).  After the mechanical 
dissociation the slice was removed from the chamber and the mechanically 
dissociated neurons were allowed to settle to the bottom.  The same protocol 
described for the whole-cell voltage clamp recordings in the slice was used with 
the mechanically dissociated neurons.  The nominally calcium free solution used 
in the mechanically dissociated neuron experiments consisted of the following 
composition: 145 mM NaCl, 5 mM KCl, 10 mM HEPES, 2 mM MgCl2 and 10 mM 
glucose (pH to 7.4 with NaOH).   
 
Protocol and analysis for mIPSC experiments.  After the membrane of the cell 
was ruptured, the control solution, which included 1 µM TTX in addition to the 
CNQX and AP5, was delivered through the multi-barrel perfusion pencil.  Once a 
steady state mIPSC frequency was obtained (determined from the average of at 
least two repetitive recordings), a pre-control recording was collected for at least 
60 seconds.  For the ethanol experiments, in addition to the pre-control 
recording, an ethanol recording and washout recording were collected.  The 
ethanol recoding in the slice was collected five minutes after the start of the 
ethanol perfusion while the ethanol recording in the mechanically dissociated 
neuron preparation was collected 30 seconds after the start of the ethanol 
perfusion.  The percent (%) change in mIPSC frequency, decay time and 
amplitude was calculated as follows: 100 x (“ethanol response”/((“pre-
control”+“washout”)/2))-100.  The “control” ethanol data points in the data 
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chapters went through the same protocol (pre-control, ethanol, washout) but 
were never exposed to ethanol.   
For the experiments that do not involve ethanol, there was a control 
recording and a drug recording with no washout.  The % change in mIPSC 
frequency, decay time and amplitude for these experiments was calculated as 
follows: 100 x ( |“drug response” – “control”| ) /”control”).  When different 
antagonists were tested against a drug effect on mIPSC frequency, a stable 
baseline mIPSC rate was established in the presence of the antagonist before 
exposure to the drug to avoid a summation of effects.  Therefore, for these 
experiments the baseline mIPSC frequency value in the presence of the 
antagonist served as the pre-control or control value.    
For the ethanol experiments that were conducted in the presence of a 
drug, all experiments initially used 100 mM ethanol, and if a drug treatment was 
sufficient to inhibit the ethanol effect on mIPSC frequency, this was the only 
ethanol concentration tested.  However, if 100 mM ethanol still had an effect in 
the presence of a drug treatment, additional experiments were carried out with 50 
mM ethanol, which was the lowest ethanol concentration that significantly 
increased mIPSC frequency, to determine if the antagonist was having an effect 
on lower ethanol concentrations. 
All data were expressed as the mean ± SEM.  If the control and pre-
control baseline mIPSC frequency were lower than 0.5 Hz (except for 
experiments with the pre-control value including exposure to WIN or baclofen), 
the experiment was excluded from analysis.  Addition of 50 µM bicuculline 
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methochloride, a GABAA antagonist, abolished the mIPSCs (n = 4, data not 
shown), which confirmed that the mIPSCs were GABAergic.    Data were 
analyzed with miniAnalysis software.  The mIPSC decay time was determined 
from a bi-exponential fit using miniAnalysis software.  Fast decay time (τ-fast) and 
slow decay time (τ-slow) were analyzed separately.   
 
Tissue preparation for electron microscopy.  Male Sprague-Dawley rats were 
anesthetized with sodium pentobarbital (60 mg/kg, intraperitoneal).  After 
inducing deep anesthesia, rats were intracardially perfused with heparinized 
saline followed by 500 ml of fixative.  The fixative was a mixture of 2% 
paraformaldehyde and 2% glutaraldeyhde in phosphate buffer (0.1 M, pH 7.4).  
The brains were removed and postfixed with the same fixative for 2 hours at 4ºC.  
Brains were sectioned with a vibratome (40-60 µM) and collected in cold 
phosphate buffer.   
 
Tissue staining for electron microscopy.  Cerebellar areas of interest were 
excised, cryoprotected in 30% glycerol, quick frozen, freeze-substituted in a 
Leica Electron Microscopy Automatic Freeze Substitution System, and 
embedded in Lowicryl HM-20. Sections were cut at ~90 nm with an 
ultramicrotome and collected on nickel grids.  The sections were incubated with 
normal rabbit serum for 20 minutes to suppress nonspecific binding and then 
incubated overnight on a shaker at room temperature with the IP3R primary 
antibody (goat, 1 : 30K), which has been characterized previously (Sharp et al., 
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1993a).  Following overnight incubation, the sections were rinsed and incubated 
for 20 minutes in normal rabbit serum.  The sections were incubated with rabbit 
anti-goat Immunoglobulin G conjugated to 10 nm gold (Ted Pella, 1:15) for two 
hours at room temperature.  After rinsing, the sections were counterstained with 
1% uranyl acetate followed by Sato’s lead and examined with a Philips Tecnai 
electron microscope (Hillsboro, OR) at 80 kV.  Images were collected with a 
Gatan 12-bit 1024 x 1024 CCD camera (Pleasanton, CA). 
 
Quantitative analysis for electron microscopy.  Attention was restricted to 
Purkinje cell and molecular layers of the cerebellum.  Once a suitable area was 
found, pictures of the field were taken at x6500 magnification and saved for later 
analysis.  For analysis, profiles representing GABAergic presynaptic terminals, 
glutamatergic presynaptic terminals, parallel fibers, and Purkinje cell dendrites 
were identified and gold particles coding for IP3R were counted for the identified 
profiles.  Using Image J software, the area of the profile was determined.  The 
number of particles per square µM was determined and data were expressed as 
the mean ± SEM.  IP3R staining associated with mitochondria or the plasma 
membrane was excluded from analysis because of potential nonspecific staining.  
Parallel fibers were analyzed as bundles, as opposed to individual fibers, and 
underwent additional analysis to account for the plasma membrane around each 
fiber.  Specifically, after the area of the parallel fiber bundle was calculated, the 
number of individual fibers within the group was counted and multiplied by the 
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calculated average area of the membrane surrounding the individual fiber.  This 
value was subtracted from the area of the parallel fiber bundle. 
In experiments that did not include a GABA antibody, visual assessments 
were made to differentiate between GABAergic terminals and glutamatergic 
terminals.  The glutamatergic synapse has an asymmetric synapse due to a thick 
postsynaptic density (Palay and Chan-Palay, 1974).  GABAergic synapses have 
a symmetric synapse that is less pronounced compared to the glutamatergic 
synapse.  GABA terminals contain a mixture of flattened, smaller vesicles and 
spherical vesicles compared to the glutamate terminals that contain only 
spherical vesicles (Palay and Chan-Palay, 1974).  I found that the GABAergic 
terminals were generally larger than the glutamatergic terminals.  In the region 
examined, GABA presynaptic terminals are believed to originate from either 
basket cells or stellate cells.  Golgi cells are also GABAergic, but are only found 
in the granule cell layer.  The glutamatergic synapses were either parallel fibers 
or climbing fibers.     
  
Statistics.  Paired Student’s t-test, Student’s t-test, one-way analysis of variance 
(ANOVA) and Dunnett’s post hoc test were performed as indicated.  A two-tailed 
p value less than 0.05 was accepted as statistically significant.   
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Drug Name Mechanism Supplier Solvent [Stock]  Storage 
1,2-Bis(2-
aminophenoxy)ethane-
N,N,N′,N′-tetraacetic acid 
tetrapotassium salt 
(BAPTA) 
membrane 
impermeable 
calcium 
chelator 
Anapec internal 
solution 
 -20°C  
1,2-Bis(2-aminophenoxy) 
ethane-N,N, N′,N’-
tetraacetic acid tetrakis 
(acetoxymethyl ester) 
(BAPTA-AM) 
membrane 
permeable 
calcium 
chelator 
Sigma DMSO 1000x -20°C 
2′,3′-Dideoxyadenosine 
(DDA) 
adenylate 
cyclase 
antagonist 
Sigma DMSO 1000x -20°C 
2-Aminoethoxy 
diphenylborane  
(2-APB) 
IP3R antagonist Tocris DMSO 1000x -20°C 
9-(Tetrahydro-2-furanyl)-
9H-purin-6-amine 
(SQ 22536) 
adenylate 
cyclase 
antagonist 
Sigma dd H20 500x -20°C 
AM-251 cannabinoid 1 
receptor 
antagonist 
Tocris DMSO 5000x -20°C 
Baclofen GABAB receptor 
agonist 
Tocris dd H20 1000x -20°C 
Bafilomycin A1 proton pump 
inhibitor 
Alexis DMSO 1000x -20°C 
Bicuculline methochloride GABAA receptor 
antagonist 
Tocris dd H20 1000x -20°C 
Cadmium chloride 
(CdCl2) 
voltage-
dependent Ca2+ 
channel 
inhibitor 
Sigma dd H20 1000x RT 
CGP 52432 GABAB receptor 
antagonist 
Tocris dd H20 1000x -20°C 
Chelerythrine chloride PKC antagonist Tocris dd H20 1000x -20°C 
Cyano-7-nitroquinoxaline-
2,3-dione 
(CNQX) 
ionotropic 
glutamate 
receptor 
antagonist 
Sigma dd H20 1000x -20°C 
D-2-amino-5-
phosphonopentanoate 
(AP5) 
NMDA receptor 
antagonist 
Sigma dd H20 1000x -20°C 
Dibutyryl-cAMP sodium 
salt 
(dBcAMP) 
PKA agonist Tocris dd H20 1000x -20°C 
Edelfosine PLC antagonist Tocris dd H20 1000x -20°C 
Epsilon-V1-2 PKCε 
antagonist 
Anaspec dd H20 1000x -20°C 
H-89 PKA antagonist Sigma dd H20 1000x -20°C 
JNJ 16259685 mGluR1 
antagonist 
Tocris DMSO 1000X -20°C 
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Drug Name Mechanism Supplier Solvent [Stock]  Storage 
N-(2,6-Dimethylphenyl 
carbamoylmethyl)triethyl 
ammonium bromide 
(QX-314) 
voltage 
dependent 
sodium channel 
inhibitor 
Sigma internal  
solution 
 -20°C 
Noradrenaline (+)-bitartrate 
salt 
(Norepinephrine) 
adrenergic 
receptor 
agonist 
Sigma dd H20 1000x Day of 
use 
Phorbol 12-myristate 13-
acetate 
(PMA) 
PKC agonist Tocris DMSO 1000x -20°C 
Protein kinase C inhibitor 
Peptide [19-36] 
(PKC(19-36)) 
membrane 
impermeable 
PKC antagonist 
Calbio-
chem 
dd H20 1000x -20°C 
Protein kinase inhibitor-(6-
22)-amide 
(PKI) 
membrane 
impermeable 
PKA antagonist 
Tocris dd H20 1000x -20°C 
Rp-Adenosine 3′,5′-cyclic 
monophosphorothioate 
triethylammonium salt 
hydrate 
(Rp-cAMP) 
PKA antagonist Sigma dd H20 1000x -20°C 
Ryanodine RyR antagonist Calbio- 
chem 
aCSF 10x -20°C 
SC9 PKC agonist Tocris DMSO 1000x -20°C 
Tetrodotoxin 
(TTX) 
voltage-
dependent Na+ 
channel 
antagonist 
Sigma dd H20 1000x 4°C 
Thapsigargin SERCA pump 
inhibitor 
Tocris DMSO 1000x -20°C 
WIN 55,212-2 mesylate 
(WIN) 
cannabinoid 1 
receptor 
agonist 
Tocris DMSO 5000x -20°C 
 
Table 2.1.  Information for each drug used in the experiments.   
 
 
 
 
 
 
 
 
 
 
 
  
Chapter III: The Effect of Ethanol on GABA Release 
 
INTRODUCTION 
The effect of ethanol on spontaneous and evoked neurotransmitter 
release can be measured in an in vitro slice preparation.  Spontaneous and 
evoked neurotransmitter release differ in their dependence on action potentials: 
spontaneous neurotransmitter release occurs in the absence of action potentials, 
while action potentials are necessary for evoked neurotransmitter release.  To 
study the mechanism of ethanol-enhanced GABA release, I determined if ethanol 
could increase GABA release in the chosen model system, the interneuron-
Purkinje cell synapse.  When GABA is released from the interneuron presynaptic 
terminals, it binds to and opens the GABAA receptors on the cerebellar Purkinje 
neuron.  The whole-cell voltage clamp technique measures the flow of chloride 
through the GABAA receptor in response to GABA binding and records this 
GABAA receptor-mediated chloride flux.  When TTX is applied to block action 
potentials, this GABAA receptor-mediated chloride flux response is known as a 
miniature inhibitory postsynaptic current (mIPSC).  An increase in the frequency 
of the mIPSC events is interpreted as an increase in spontaneous GABA release. 
When measuring evoked GABA release, a stimulator artificially creates an 
action potential to stimulate GABA release and this recorded chloride flux 
response is known as an evoked inhibitory postsynaptic current (eIPSC).  
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However, unlike spontaneous release, there is no direct readout for changes in 
presynaptic activity with analysis of eIPSCs.  Therefore, a paired pulse ratio 
(PPR) is used to make this assessment, which determines if there is a change in 
the ratio of the amplitude of two closely-spaced eIPSCs (eIPSC2/eIPSC1) that are 
the result of two stimuli applied to the brain slice 20-200 milliseconds apart (for 
review see Zucker, 1989).  If there is a change in the amplitude of the first 
eIPSC, it reflects a change in neurotransmitter release probability.  If there is a 
change in the amplitude of the second eIPSC, it could reflect a change in 
residual calcium, postsynaptic receptor desensitization or a change in action 
potential duration.  The drug effect on the PPR is inversely related to the drug 
effect on evoked neurotransmitter release (Siggins et al., 2005).   Hence, if 
ethanol increases evoked GABA release, there would be a decrease in the PPR.  
At the interneuron-Purkinje cell synapse, I determined the effect of ethanol on 
mIPSC frequency and the PPR to measure ethanol-induced changes in 
spontaneous and evoked GABA release, respectively. 
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RESULTS 
Ethanol selectively increases mIPSC frequency in the slice.  Compared to 
control (-0.6 ± 2.8%, n = 8), the mIPSC frequency of cerebellar Purkinje neurons 
was significantly increased by 50 mM (10.9 ± 2.0%, n = 9), 75 mM (18.6 ± 3.5%, 
n = 9) and 100 mM (22.9 ± 3.8%, n = 12) ethanol, but not by 25 mM (2.2 ± 3.1%, 
n = 12) ethanol, as illustrated in Figure 3.1A.  There was a significant linear trend 
across concentrations for the ethanol effect on mIPSC frequency (r = .69, p<.05), 
which shows that ethanol dose-dependently increased mIPSC frequency.  In 
contrast, none of the ethanol concentrations changed the mIPSC decay time and 
amplitude (data not shown, see Ming et al., 2006).  A trace and a cumulative 
probability curve from a representative neuron are shown in Figure 3.1B and 
3.1C, respectively.  In Figure 3.1C, ethanol shifts the distribution of the interevent 
interval curve to the left, which is interpreted as ethanol increasing mIPSC 
frequency.  The lack of ethanol effect on mIPSC decay time and amplitude from 
the same representative neuron is shown in Figure 3.1D.  These results suggest 
that ethanol is increasing spontaneous GABA release in the slice preparation. 
 
Ethanol selectively increases mIPSC frequency in the mechanically 
dissociated neuron preparation.  Mechanically dissociated neurons were also 
used to determine if ethanol increases spontaneous GABA release.  The 
mechanically dissociated neuron preparation consists of the Purkinje cell soma 
and the attached presynaptic terminals (Akaike and Moorhouse, 2003).    
Compared to mIPSCs that were recorded in the slice, baseline mIPSC decay 
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time, rise time, and amplitude were all different in the mechanically dissociated 
neuron preparation (see Table 3.1).  Similar to data collected in the slice, 50 mM 
(36.4 ± 9.1%, n = 9) and 100 mM (22.0 ± 11.4%, n = 10) ethanol significantly 
increased the mIPSC frequency of mechanically dissociated cerebellar Purkinje 
neurons compared to control (-10.8 ± 6.2%, n = 9, Fig. 3.2A), while having no 
effect on mIPSC decay time and amplitude (data not shown).  A representative 
neuron showing that 100 mM ethanol increases mIPSC frequency in a 
mechanically dissociated neuron preparation is shown in Figure 3.2B.  It should 
be noted that 50 mM ethanol significantly increased mIPSC frequency to a 
greater extent in the mechanically dissociated neuron preparation compared to 
the slice (p<.05, Student’s t-test).  Overall, these results suggest that ethanol 
increases spontaneous GABA release in the mechanically dissociated neuron 
preparation.  
 
Ethanol does not increase mIPSC frequency in the presence of bafilomycin 
A1.  To confirm that the ethanol-induced increase in mIPSC frequency is the 
result of an increase in vesicular GABA release, a vacuolar-type proton pump 
inhibitor, bafilomycin A1, was used (Bowman et al., 1988).  Inhibition of the proton 
pump eliminates the pH and electrical gradients that are necessary for GABA 
transporters to fill the vesicles with GABA (Maycox et al., 1990; Drose and 
Altendorf, 1997).  Following at least a two hour incubation of the slice with 2 µM 
bafilomycin A1, 100 mM ethanol did not increase mIPSC frequency (0.022 ± 0.01 
Hz, n = 5) compared to control (0.022 ± 0.008 Hz, Fig. 3.2C).  These results 
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suggest that the ethanol-induced increase in mIPSC frequency is due to the 
release of GABA-filled vesicles. 
 
Ethanol decreases the PPR.  The PPR was significantly decreased by 50 mM 
ethanol (16.2 ± 6.3%, n = 10), 75 mM ethanol (19.8 ± 3.5%, n = 9), and 100 mM 
ethanol (22.5 ± 7%, n = 9), but not by 25 mM ethanol (4.2 ± 4.3%, n = 10) and 0 
mM ethanol (3.9 ± 2.7%, n = 10), as illustrated in Figure 3.3A.  There was a 
significant linear trend across concentrations for the ethanol effect on the PPR (r 
= -.45, p<.05), which shows that ethanol dose-dependently decreased the PPR.  
In Figure 3.3B, averaged PP traces from a representative neuron show that 100 
mM ethanol decreases the ratio of the amplitude of the second eIPSCs to the 
first compared to the pre-control and washout.  These results suggest that 
ethanol increases evoked GABA release at the interneuron-Purkinje cell 
synapse.   
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DISCUSSION 
I found that ethanol increased mIPSC frequency at the interneuron-
Purkinje cell synapse while having no effect on mIPSC decay time or amplitude 
in both the slice and mechanically dissociated neuron preparation.  These 
findings are consistent with many studies that have shown ethanol increases 
mIPSC frequency while having no effect on mIPSC decay time (Sebe et al., 
2003; Li et al., 2006; Ming et al., 2006; Zhu and Lovinger, 2006).  The lack of 
ethanol effect on mIPSC decay time indicates that ethanol did not alter 
postsynaptic GABAA receptor function in these recording conditions.  In addition, 
ethanol did not alter mIPSC amplitude, which is another indication that ethanol 
does not affect postsynaptic GABAA receptors.  While there was no postsynaptic 
ethanol effect in the current study, the possibility cannot be ruled out that ethanol 
is having a postsynaptic effect under physiological conditions.  The intracellular 
milieu of the postsynaptic neuron is altered during whole-cell voltage clamp 
recordings (for review see Sarantopoulos et al., 2004); moreover, the presence 
of high intracellular chloride, as was used in the present study, reduces the 
ethanol effect on GABAA receptors in the hippocampus (Silberman et al., 2005).   
In addition to the slice, I utilized a mechanically dissociated neuron 
preparation in this study.  This preparation consists of a soma and the attached 
presynaptic terminals (Akaike and Moorhouse, 2003); therefore, communication 
from nearby glia and neurons is eliminated.  Because ethanol increased 
spontaneous GABA release in the mechanically dissociated neuron preparation, 
the GABAergic presynaptic terminals are the likely source of the GABA released 
41 
 
onto the Purkinje neurons.  Additionally, in the presence of bafilomycin A1, a drug 
that blocks vesicles from filling with GABA, ethanol had no effect on mIPSC 
frequency. These results provide further evidence that ethanol is acting at the 
interneuron presynaptic terminal to increase GABA release.  Overall, this work 
and the work of others suggest that ethanol increases spontaneous GABA 
release in multiple brain regions through a presynaptic mechanism.  
There were some differences between the slice and mechanically 
dissociated neuron preparation.  Specifically, I found differences in baseline 
mIPSC decay time, rise time, and amplitude, and it is thought that the 
mechanical dissociation procedure alters presynaptic terminal excitability (Akaike 
and Moorhouse, 2003).  However, ethanol increased mIPSC frequency in both 
preparations.  It is important to note that 50 mM ethanol increased mIPSC 
frequency to a higher degree in the mechanically dissociated neuron preparation.  
Previously, ethanol was shown to increase GABA release using this same 
preparation with basolateral amygdala neurons (Zhu and Lovinger, 2006).  These 
investigators also saw a larger effect of ethanol on GABA release in the 
mechanically dissociated neuron preparation compared to the slice.  Because the 
mechanically dissociated neuron preparation allows for instantaneous access of 
ethanol to the neuron, the effect of ethanol can be seen on a seconds timescale 
compared to the minutes required in the slice.  Therefore, Zhu and Lovinger 
(2006) hypothesized that the additional time it takes to see an ethanol effect in 
the slice allows for tolerance to develop, resulting in an overall smaller ethanol 
effect in the slice compared to the mechanically dissociated neuron preparation. 
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In addition to increasing mIPSC frequency, ethanol decreased the PPR, 
which is interpreted as ethanol increasing evoked GABA release.  Ethanol 
decreases the PPR in central nucleus of the amygdala neurons (Roberto et al., 
2003), hippocampal CA1 pyramidal neurons (Weiner et al., 1997; Ariwodola and 
Weiner, 2004), VTA neurons (Theile et al., 2008) and cerebellar Purkinje neurons 
(Criswell et al., 2008).  Additionally, if there is no ethanol effect on mIPSC 
frequency, there is also no effect on the PPR (Criswell et al., 2008; Jia et al., 
2008). 
Interestingly, Mameli and colleagues (2008) found that at the interneuron-
Purkinje cell synapse ethanol increases spontaneous GABA release but 
increases evoked GABA release in a location-dependent manner.  When the 
stimulator is in the outer third of the molecular layer (i.e. distal stimulation), which 
is the location of the interneuron stellate cells, ethanol decreases the PPR.  
However, if the stimulator is moved to the inner third of the molecular layer (i.e. 
proximal stimulation), which is the location of the interneuron basket cells, 
ethanol has no effect on the PPR.  A similar phenomenon is observed in the 
basolateral amygdala and hippocampus, except that the proximal stimulation 
elicits an ethanol effect while the distal stimulation is without effect (Wu et al., 
2005; Silberman et al., 2008).  In the present protocol, the stimulator was placed 
in the middle of the molecular layer, which most likely resulted in stimulation of 
both the stellate and the basket cells. 
Overall, I found that ethanol increases mIPSC frequency and decreases 
the PPR at the interneuron-Purkinje cell synapse, which suggests that ethanol 
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increases both spontaneous and evoked GABA release, respectively.  The 
mechanically dissociated neuron study and the bafilomycin A1 study provided 
evidence that the ethanol effect on mIPSC frequency involves an increase in the 
vesicular release of GABA.  I will primarily utilize the mIPSC technique to 
investigate the mechanism of ethanol-enhanced GABA release because analysis 
of mIPSCs provides a direct way to assess changes in neurotransmitter release, 
and I have more thoroughly characterized the source of the GABA release in this 
technique.   
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 Frequency 
(Hz) 
τ-fast  
(ms) 
τ-slow  
(ms) 
Rise Time 
(ms) 
Amplitude 
(pA) 
Slice 2.2 ± 0.4 11.9 ± 0.6 11.9 ± 0.6 2.6 ± 0.1 15.9 ± 1.6 
MDN 1.4 ± 0.4 5.6 ± 0.5* 16.9 ± 2.0* 1.0 ± 0.1* 29.4 ± 3.9* 
 
Table 3.1.  A comparison of mIPSC properties between the mechanically 
dissociated neuron (MDN) preparation and the slice at the interneuron-
Purkinje cell synapse.  There was no significant effect on mIPSC frequency 
between the two groups.  There was a significant decrease in the mIPSC fast 
decay time (τ-fast) and rise time and an increase in the mIPSC slow decay time (τ-
slow) and amplitude in the MDN preparation compared to the slice  (*, p<.05, 
Student’s t test).   
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Figure 3.1. In the slice ethanol increased mIPSC frequency and had no 
effect on mIPSC amplitude and decay time. A, there was an increase in 
mIPSC frequency at 50, 75, and 100 mM ethanol (*, p<.05, one-way ANOVA, 
Dunnett’s post hoc test). B, a trace from a representative neuron showing the 
effect of 100 mM ethanol on mIPSC frequency. C, a cumulative frequency 
histogram  from the same representative neuron demonstrating the effect of 100 
mM ethanol on the interevent interval curve. D, a trace from the same 
representative neuron showing the effect of 100 mM ethanol on mIPSC decay 
time and amplitude.  
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Figure 3.2. Ethanol increased mIPSC frequency in the mechanically 
dissociated neuron preparation and had no effect in the presence of 
bafilomycin A1. A, there was an increase in mIPSC frequency at 50 and 100 mM 
ethanol (EtOH) in the mechanically dissociated neuron preparation (*, p<.05, 
one-way ANOVA, Dunnett’s post hoc test). B, a trace from a representative 
neuron demonstrating the effect of 100 mM ethanol on mIPSC frequency in the 
mechanically dissociated neuron preparation. C, incubating the slice with 
bafilomycin A1 (Baf A1) prevented 100 mM ethanol from increasing mIPSC 
frequency.   
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Figure 3.3.  Ethanol decreased the paired-pulse ratio. A, the paired-pulse 
ratio (PPR) was decreased at 50, 75 and 100 mM ethanol (*, p<.05, paired 
Student’s t test). B, traces from a representative neuron demonstrating the effect 
of 100 mM ethanol on the ratio of the amplitude of the second evoked inhibitory 
postsynaptic current (eIPSC) to the amplitude of the first eIPSC. 
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 Chapter IV: Calcium Signaling and Ethanol-enhanced GABA release 
 
INTRODUCTION 
I provided evidence that ethanol increases GABA release at the 
interneuron-Purkinje cell synapse, but the intracellular messengers mediating this 
effect are unknown.  One possibility is calcium because of the imperative role it 
plays in a number of neuronal processes, including all neurotransmitter release.  
It is generally accepted that physiologically relevant ethanol concentrations 
increase levels of intracellular calcium (Daniell and Harris, 1989; Mironov and 
Hermann, 1996; Xiao et al., 2005).  Moreover, changes in presynaptic 
intracellular calcium levels can alter spontaneous and evoked GABA release 
(Bardo et al., 2002; Bardo et al., 2006; Yamasaki et al., 2006; Glitsch, 2008).  
Therefore, it seems plausible that ethanol increases spontaneous GABA release 
through a mechanism that involves an increase in intracellular calcium.   
This increase in intracellular calcium can occur through an increase in 
calcium influx via voltage-dependent calcium channels, receptor-operated 
channels, and store-operated channels (SOCs) or through an increase in calcium 
release from the inositol 1,4,5-trisphosphate receptors (IP3Rs) and ryanodine 
receptors (RyRs) located on the internal stores (i.e. endoplasmic reticulum).  The 
endoplasmic reticulum is a single, continuous intracellular organelle that extends 
throughout the neuron- from the dendrites to the presynaptic terminals (for review 
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see Verkhratsky, 2005).  I tested the hypothesis that ethanol enhances GABA 
release at the interneuron-Purkinje cell synapse through a presynaptic calcium-
dependent mechanism.  I then determined the origin of the calcium that regulated 
the increase in GABA release. 
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RESULTS 
The ability of ethanol to increase mIPSC frequency is occurring through a 
presynaptic, calcium-dependent mechanism.  The slices were incubated with 
100 µM BAPTA-AM, a membrane permeable calcium-chelator, and it was 
determined if ethanol could increase mIPSC frequency in these conditions.  The 
ability of ethanol to increase mIPSC frequency was blocked in the presence of 
BAPTA-AM compared to control (7.4 ± 2.7%, n = 8, Fig. 4.1A).  These results 
suggest that ethanol is increasing spontaneous GABA release through a calcium-
dependent mechanism.   
Because BAPTA-AM was applied to the bath, it could be acting at the 
postsynaptic neuron instead of the presynaptic neuron.  This could alter the 
release of a calcium-dependent retrograde messenger, which could be 
responsible for the presynaptic effect of ethanol in lieu of ethanol acting directly 
on the presynaptic site.  Therefore, BAPTA tetrapotassium salt (30 mM), which is 
membrane impermeable, was included in the internal solution to limit BAPTA 
exposure to the postsynaptic neuron.  Compared to control (2.4 ± 2.8%, n = 7, 
Fig. 4.1B), 50 mM (20.0 ± 5.6%, n = 8) and 100 mM (23.9 ± 4.3%, n = 6) ethanol 
were still able to significantly increase mIPSC frequency with 30 mM BAPTA in 
the internal solution.  In addition, inclusion of BAPTA in the internal solution 
significantly increased baseline mIPSC decay time (control: 11.8 ± 0.3 ms vs. 
BAPTA: 14.1 ± 1.1 ms, Fig. 4.1C) and significantly decreased baseline mIPSC 
amplitude (control: 15.4 ± 0.7 pA vs. BAPTA: 12.2 ± 1.1 pA, Fig. 4.1C) and 
frequency (control: 2.5 ± 0.3 Hz vs. BAPTA: 1.8 ± 0.3 Hz, Fig. 4.1C).  These data 
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suggest that BAPTA was reaching the postsynaptic site but did not inhibit 
ethanol-enhanced spontaneous GABA release.  Therefore, the ability of BAPTA-
AM to inhibit ethanol-enhanced spontaneous GABA release is occurring through 
a presynaptic mechanism.      
 
Influx of extracellular calcium is not required for ethanol to increase mIPSC 
frequency.  A nominally calcium free extracellular (0 mM Ca2+ext) solution was 
used to eliminate all sources of extracellular calcium that could contribute to the 
ethanol-induced increase in mIPSC frequency.  When conducting this experiment 
in a slice, extended exposure to the 0 mM Ca2+ext solution is necessary to ensure 
that the solution is reaching the neuron; however, extended exposure to the 0 
mM Ca2+ext solution can also reduce intracellular calcium levels, which is not 
desirable because the contribution of extracellular calcium needs to be 
investigated independently.  Therefore, the mechanically dissociated neuron 
preparation was used because it allows for almost instantaneous access of the 
solution to the neuron and dramatically reduces the possibility of the 0 mM 
Ca2+ext solution affecting levels of intracellular calcium.  In the presence of the 0 
mM Ca2+ext solution, 50 mM (68.7 ± 11.7%, n = 9) and 100 mM (65.8 ± 13.7%, n 
= 8) ethanol significantly increased mIPSC frequency compared to control (-6.2 ± 
3.8%, n = 7, Fig. 4.2A).  Interestingly, the effect of ethanol on mIPSC frequency 
was significantly enhanced in the presence of the 0 mM Ca2+ext solution 
compared to the effect of ethanol on mIPSC frequency in control conditions (see 
Fig. 3.2A, p<.05, Student’s t test).  Compared to neurons exposed to control 
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conditions (1.7 ± 0.4 Hz, n = 11), the 0 mM Ca2+ext solution did not significantly 
decrease baseline mIPSC frequency (0.9 ± 0.2 Hz, n = 7), although there was a 
trend towards a decrease.  To confirm that the solution around the neuron was 
free of calcium, the ability of the 0 mM Ca2+ext solution to block calcium-
dependent GABA release was tested.  Compared to control (0.5 ± 0.2 Hz, n = 4), 
addition of a high potassium (K+, 15 mM) HEPES buffered solution in the 
absence of TTX increased the frequency of spontaneous IPSCs (5.2 ± 1.3 Hz, n 
= 4) by depolarizing the presynaptic terminal and activating voltage-dependent 
calcium channels, while a 0 mM Ca2+ext solution with the same high K+ 
concentration returned the spontaneous IPSC frequency to baseline values (0.3 
± 0.03 Hz, n = 4).   
Similar experiments were conducted with cadmium chloride (CdCl2), a 
nonspecific voltage-dependent calcium channel inhibitor, to confirm the lack of 
involvement of extracellular calcium influx in the mechanism of ethanol-enhanced 
GABA release.  As expected, 50 mM (40.6 ± 11.6%, n = 10) and 100 mM (50.3 ± 
10.3%, n = 9) ethanol still significantly increased mIPSC frequency in the 
presence of 50 µM CdCl2 compared to control (-4.8 ± 8.5%, n = 11, Fig. 4.2A).  
Interestingly, in the presence of 50 µM CdCl2 the effect of ethanol did not always 
wash out, as demonstrated with a representative neuron in Figure 4.2B and C.  
Because a lack of washout could affect the calculated percent change in mIPSC 
frequency (see general methods), all of the CdCl2 mechanically dissociated 
neuron data were reanalyzed without the washout included (data not shown).  
This additional analysis resulted in the same conclusion made from the data with 
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the washout included.  Compared to neurons exposed to control conditions (1.4 ± 
0.4 Hz, n = 9), 50 µM CdCl2 did not significantly decrease baseline mIPSC 
frequency (0.9 ± 0.2 Hz, n = 11), although there was a trend towards a decrease.  
The same control with the high K+ HEPES buffered solution was conducted in the 
presence of 50 µM CdCl2.  Compared to control (1.0 ± 0.6 Hz, n = 3), addition of 
a high K+ HEPES buffered solution increased spontaneous IPSC frequency (14.1 
± 2.8 Hz, n = 3, p<.05, paired Student’s t test), while addition of 50 µM CdCl2 to 
the high K+ HEPES buffered solution returned the frequency to baseline values 
(1.5 ± 0.7 Hz, n = 3).  These data collectively suggest that influx of extracellular 
calcium is not required for ethanol-enhanced spontaneous GABA release.   
 
Inhibition of calcium release from internal stores prevents the ethanol-
induced increase in mIPSC frequency.  To determine the involvement of 
internal calcium stores in ethanol-enhanced spontaneous GABA release, a 
sarco/endoplasmic-reticulum calcium ATPase (SERCA) pump inhibitor, 
thapsigargin, was used to prevent calcium reuptake into internal stores.  
Preventing calcium reuptake will eventually lead to depletion of the internal 
stores because the IP3Rs and RyRs are continually releasing calcium from the 
internal stores; however, this process can take an extended period of time 
because of slow calcium release from the IP3Rs and RyRs (Simkus and Stricker, 
2002).  Therefore, to diminish internal calcium stores at a faster rate I used a 
high potassium extracellular (K+ext) solution (15 mM) to depolarize the 
presynaptic terminals, which increases the rate of calcium release from the IP3Rs 
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and RyRs (Simkus and Stricker, 2002).  Any effect of the high K+ext solution on 
the mIPSCs disappeared within 2 minutes (n = 4, data not shown), and exposing 
the slice to the high K+ext solution had no effect on the ability of ethanol to 
increase mIPSC frequency after the high K+ext solution had been washed out 
(27.8 ± 5.0%, n = 3).  After completing the high K+ext solution protocol in the 
presence of thapsigargin, ethanol was not able to increase mIPSC frequency (5.2 
± 4.7, n = 11, Fig. 4.3A).  A representative neuron demonstrating the lack of 
ethanol effect on mIPSC frequency in the presence of thapsigargin is shown in 
Figure 4.3B.  Compared to neurons exposed to control conditions (2.2 ± 0.4 Hz, 
n = 9), depleting internal stores did not have an effect on baseline mIPSC 
frequency (2.1 ± 0.4 Hz, n = 11).       
Because depleting internal calcium stores prevented ethanol from 
increasing spontaneous GABA release, I next determined whether inhibition of 
the IP3Rs and RyRs would prevent ethanol from increasing spontaneous GABA 
release.  The IP3R antagonist, 2-APB (14 µM), significantly blocked the ability of 
100 mM ethanol to increase mIPSC frequency (5.1 ± 2.7%, n = 10, Fig. 4.3A).  2-
APB (14 µM) did not have a significant effect on baseline mIPSC frequency (1.8 
± 0.3 Hz, n = 10) compared to control (2.2 ± 0.4 Hz, n = 9).  Subsequently, the 
effect of ethanol on mIPSC frequency in the presence of a RyR antagonist was 
determined.  At a concentration of 100 µM, ryanodine is an open-channel blocker 
of the RyR; however, it can take up to two hours to block the RyRs because of 
slow channel opening (Simkus and Stricker, 2002).  To avoid this difficulty that is 
sometimes overlooked (Llano et al., 2000; Bardo et al., 2002), cells were 
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exposed to the high K+ext solution (Simkus and Stricker, 2002) to open the 
presynaptic RyRs and allow access of ryanodine to the channel.  Inhibition of the 
RyRs was sufficient to block the effect of ethanol on mIPSC frequency (8.7 ± 
4.6%, n = 13, Fig. 4.3A).  Compared to neurons exposed to control conditions 
(2.2 ± 0.4 Hz, n=9), 100 µM ryanodine did not have an effect on baseline mIPSC 
frequency (2.2 ± 0.2 Hz, n = 13).  These results suggest that calcium release 
from internal stores plays an important role in ethanol-enhanced spontaneous 
GABA release. 
 
The cerebellar interneuron presynaptic terminals are immunopositive for 
IP3R.  To add further support to the conclusion that calcium release from internal 
stores is necessary for ethanol to increase spontaneous GABA release from the 
cerebellar interneurons, I used double-label immunogold electron microscopy to 
determine if IP3Rs are expressed in the GABAergic interneuron presynaptic 
terminals.  IP3R and GABA immunogold labeling was colocalized in 18 out of the 
30 (60%) presynaptic GABAergic terminals.  In the absence of the IP3R antibody, 
IP3R and GABA immunogold labeling was colocalized in 4 out of the 30 (13%) 
presynaptic GABAergic terminals.  This semi-quantitative analysis demonstrates 
that at least 45% of the presynaptic GABAergic terminals in the molecular layer 
are immunopositive for IP3R and that there is minimal nonspecific binding with 
the IP3R primary antibody. 
In sections stained with just the IP3R antibody, the amount of IP3R staining 
in the GABA terminals, glutamate terminals, parallel fibers and Purkinje cell 
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dendrites was quantified.  The densest staining was found in Purkinje cell 
dendrites (49.5 ± 6.4 particles/µm2, n = 47, Figure 4.4A).  GABA terminals (10.9 ± 
2 particles/µm2, n = 34), glutamate terminals (9.8 ± 1.8 particles/µm2, n = 39), 
and parallel fibers (4.5 ± 1 particles/µm2, n = 29, Fig. 4.4A) also contained IP3R.    
Compared to the parallel fibers, taken as a control for background staining, IP3R 
expression was significantly greater in the Purkinje cell dendrites, GABA 
terminals and glutamate terminals.  Micrographs of a glutamatergic presynaptic 
terminal and a GABAergic presynaptic terminal immunopositive for IP3R are 
shown in Figure 4.4B and 4.4C, respectively.  Results from an experiment 
conducted with serial sections were also consistent with IP3R staining being 
present in the GABAergic presynaptic terminals (data not shown).  Additionally, 
every section for a profile was not immunopositive for IP3R.  Overall, these 
results suggest that there is IP3R expression in the presynaptic terminals of the 
cerebellar interneurons.     
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DISCUSSION 
The purpose of this study was to determine the role of calcium signaling in 
ethanol-enhanced spontaneous GABA release.  Because incubating the slices 
with BAPTA-AM prevented ethanol from increasing spontaneous GABA release, 
the mechanism of ethanol-enhanced GABA release is dependent on calcium 
signaling.  Ethanol was still able to increase spontaneous GABA release with 
BAPTA in the internal solution, which suggests that neither postsynaptic calcium 
nor calcium-dependent retrograde messengers are responsible for the effect of 
ethanol on spontaneous GABA release.  This finding is consistent with previous 
results (Zhu and Lovinger, 2006).  Therefore, ethanol is acting through a 
presynaptic, calcium-dependent mechanism to increase spontaneous GABA 
release. 
Voltage-dependent calcium channels, receptor-operated channels and 
SOCs increase intracellular calcium levels by allowing extracellular calcium to 
flow into the neuron.  A 0 mM Ca2+ext solution was used to eliminate the 
functionality of these channels to determine their involvement in the mechanism 
of ethanol-enhanced spontaneous GABA release.  The mechanically dissociated 
neuron preparation was used for this experiment because it allows for 
instantaneous access of the 0 mM Ca2+ext solution to the neuron, which 
dramatically reduces the possibility of concomitantly reducing levels of 
intracellular calcium.  Ethanol continued to increase spontaneous GABA release 
in the presence of the 0 mM Ca2+ext solution, which suggests that extracellular 
calcium influx does not play a role in this ethanol mechanism.  Surprisingly, the 
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effect of ethanol on spontaneous GABA release in the presence of the 0 mM 
Ca2+ext solution was actually enhanced compared to control conditions.  In the 
presence of the 0 mM Ca2+ext solution, only “extracellular-calcium insensitive” 
GABA release is left, which I predict is the specific type of GABA release that 
ethanol affects.  Therefore, when the extracellular calcium sensitive mIPSCs 
were eliminated in the presence of the 0 mM Ca2+ext solution, ethanol had a 
larger effect on the % change in mIPSC frequency.   
Because influx of extracellular calcium was not required for ethanol to 
increase spontaneous GABA release, the focus shifted to calcium release from 
internal stores.  When internal stores were depleted of calcium with the 
thapsigargin protocol, ethanol was not able to increase spontaneous GABA 
release.  Additionally, there was no significant change in spontaneous GABA 
release after using the thapsigargin protocol compared to a group of control 
neurons.  In the absence of the high K+ext solution protocol, there is an increase 
in baseline mIPSC frequency in the presence of thapsigargin (Bardo et al., 2002; 
Li et al., 2004), which is consistent with calcium still being released from internal 
stores while thapsigargin is blocking calcium reuptake through the SERCA pump 
and/or activation of SOCs.  There is evidence that the effect of thapsigargin on 
mIPSC frequency subsides after a period of time when even more calcium is 
depleted from the internal stores (Li et al., 2004).  Therefore, because we used 
the high K+ext solution to deplete the stores at a faster rate, it is likely that any 
increase in mIPSC frequency due to incomplete emptying of the internal stores 
and/or activation of the SOCs occurred during exposure to the high K+ext solution.   
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After determining that calcium release from internal stores plays an 
imperative role in ethanol-enhanced spontaneous GABA release, I wanted to 
investigate whether the IP3Rs and RyRs were involved in this ethanol 
mechanism.  The IP3R antagonist, 2-APB, significantly blocked the ethanol-
induced increase in mIPSC frequency.  Even though 2-APB is the most widely 
used membrane permeable IP3R antagonist, there are questions regarding its 
selectivity with respect to intracellular calcium signaling that need to be 
discussed.  When 2-APB concentrations higher than 90 µM are used, there is a 
nonspecific calcium leak from internal stores and slight inhibition of the SERCA 
pump (Missiaen et al., 2001).  This nonspecific effect of 2-APB offers an 
explanation for the large increase in miniature excitatory postsynaptic current 
frequency (Simkus and Stricker, 2002) and mIPSC frequency (data not shown) 
seen with 2-APB concentrations higher than 80 µM.  To circumvent these 
nonspecific effects of 2-APB, a low 2-APB concentration (14 µM) was used that 
did not increase baseline mIPSC frequency, which is consistent with the work of 
others (Simkus and Stricker, 2002; Glitsch, 2006).   
There are additional 2-APB nonspecific effects that could occur at any 
concentration, including inhibition of SOCs as well as transient receptor potential 
(TRP) channels (Lievremont et al., 2005).  Calcium entry through SOCs is 
activated when internal stores are depleted of calcium (Parekh and Penner, 
1997); therefore, because inhibition of IP3Rs prevents the depletion of internal 
calcium stores, the normal functioning of the SOCs is reduced.  In addition, TRP 
channels are involved in this store-operated calcium entry mechanism (Zhu et al., 
60 
 
1996).  Therefore, because IP3Rs, SOCs, and TRP channels are mechanistically 
linked, defining the selectivity of 2-APB has been controversial (Boulay et al., 
1999; Lievremont et al., 2005).  However, 2-APB was not acting through SOCs 
and TRP channels to inhibit ethanol-enhanced spontaneous GABA release 
because removal of extracellular calcium did not prevent ethanol from increasing 
spontaneous GABA release.  Therefore, these data suggest that calcium release 
from the IP3Rs is playing a role in ethanol-enhanced spontaneous GABA release.   
Inhibition of RyRs also prevented ethanol from increasing spontaneous 
GABA release.  The fact that both an IP3R antagonist and a RyR antagonist can 
inhibit ethanol-enhanced spontaneous GABA release suggests that either both 
the IP3R and RyR are necessary for this ethanol mechanism or that inhibition of 
calcium release from the IP3R affects calcium release from the RyR, and vice 
versa.  For the latter to be true, the IP3R and RyR would have to exist on one 
internal store, but there is controversy surrounding whether separate IP3R and 
RyR stores exist.  Studies suggesting that separate stores exist were primarily 
conducted in cell lines and embryonic cultures, while studies supporting one 
internal store were conducted in primary cultures and brain slices (for review see 
Verkhratsky, 2005), which is similar to the slice preparation used in the present 
experiments.  At this time I cannot distinguish between the relative importance of 
the IP3Rs and RyRs in this ethanol mechanism; however, it is overwhelmingly 
evident that internal calcium stores play an imperative role in ethanol-enhanced 
spontaneous GABA release. 
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Because I was not able to definitively determine the involvement of the 
IP3Rs and RyRs in ethanol-enhanced spontaneous GABA release, I wanted to 
determine if IP3Rs and RyRs are expressed in the presynaptic terminals of the 
cerebellar interneurons.  An elegant study by Llano and colleagues (2000) 
provided evidence from electrophysiology, calcium imaging and 
immunohistochemistry studies that RyRs play a functional role in the generation 
of spontaneous GABA release at the interneuron-Purkinje cell synapse.  Since 
this report, there have been a number of studies confirming the role of RyRs in 
spontaneous neurotransmitter release as well as defining a role for RyRs in 
evoked transmitter release and long-term synaptic plasticity (for review see Collin 
et al., 2005b).  For these reasons, I considered electron microscopy studies 
examining RyR expression at this synapse to be unnecessary. 
Unlike the RyRs, few studies have examined whether IP3Rs are 
expressed in presynaptic terminals.  In rat barrel cortex, inhibition of IP3Rs 
reduces spontaneous glutamate release, suggesting that IP3Rs are present in 
the presynaptic terminals (Simkus and Stricker, 2002).  However, like the current 
study, this study is limited due to the potential nonspecific effects seen with the 
IP3R inhibitors (Boulay et al., 1999; Missiaen et al., 2001; Lievremont et al., 
2005).  In retinal amacrine cells, which release transmitter from dendrites, 
immunohistochemistry, electrophysiology and calcium imaging studies found that 
only the IP3Rs contribute to the release of transmitter, despite the presence of 
both the IP3R and RyR in the amacrine cell dendrites (Peng et al., 1991; Warrier 
et al., 2005).  Electron microscopy studies in the bed nucleus of the stria 
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terminalis, deep cerebellar nuclei and substantia nigra show some IP3R staining 
in synaptic terminals, but no quantification was done to further characterize this 
observation (Sharp et al., 1993b; Sharp et al., 1999).  Light microscopy studies 
found IP3R staining in the molecular layer of the cerebellum, which is described 
as “fine granular staining” suggestive of neuropil distribution (Sharp et al., 1999).  
Because of the lack of data on the presynaptic localization of IP3Rs, I conducted 
extensive experiments to determine if IP3Rs are located in the presynaptic 
terminals of cerebellar interneurons.     
IP3R staining was found in the presynaptic terminals of cerebellar 
interneurons using electron microscopy.  The IP3R antibody had been 
characterized previously (Sharp et al., 1993a), and I have shown that removal of 
the primary antibody resulted in minimal nonspecific staining.  The cerebellar 
Purkinje cells had a much higher level of IP3R staining compared to the 
presynaptic terminals and parallel fibers, which is consistent with IP3R expression 
in Purkinje cells being the highest in the brain (Worley et al., 1989).  
Unfortunately, because there was IP3R staining in all three layers (molecular, 
granule cell, and Purkinje) of the cerebellum (Sharp et al., 1999), there was not a 
straightforward negative control.  However, IP3R expression was significantly 
higher in the Purkinje cell dendrites, GABA terminals and glutamate terminals 
compared to the parallel fibers.  If one assumes that the parallel fiber staining 
represented the maximum possible level of nonspecific staining, these results 
suggest there was significant IP3R expression in the presynaptic GABAergic 
terminals.  Therefore, the large preponderance of evidence argues in favor of the 
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IP3R staining in the GABAergic presynaptic terminals reflecting actual IP3R 
expression.  While not every GABAergic terminal was immunopositive for IP3R, it 
is not known if this variability is due something biological or experimental since 
there is an inherit randomness in the labeling process. 
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Figure 4.1.  A presynaptic, calcium-dependent mechanism was responsible 
for the ethanol-induced increase in mIPSC frequency. A, incubation of the 
slice with BAPTA-AM (100 µM) prevented 100 mM ethanol (EtOH) from 
increasing mIPSC frequency (*, p<.05, Student’s t test). B, ethanol (50 and 100 
mM) still increased mIPSC frequency with 30 mM BAPTA in the internal solution 
(BAPTAint; *, p<.05, one-way ANOVA, Dunnett’s post hoc test).  C, in the 
presence of 30 mM BAPTAint, there was an increase in baseline mIPSC slow 
decay time (τ-Slow) and a decrease in baseline mIPSC amplitude and frequency 
(*, p<.05, Student’s t test).   
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Figure 4.2.  A presynaptic, calcium-dependent mechanism was responsible 
for the ethanol-induced increase in mIPSC frequency. A, incubation of the 
slice with BAPTA-AM (100 µM) prevented 100 mM ethanol (EtOH) from 
increasing mIPSC frequency (*, p<.05, Student’s t test). B, ethanol (50 and 100 
mM) still increased mIPSC frequency with 30 mM BAPTA in the internal solution 
(BAPTAint; *, p<.05, one-way ANOVA, Dunnett’s post hoc test).  C, in the 
presence of 30 mM BAPTAint, there was an increase in baseline mIPSC slow 
decay time (τ-Slow) and a decrease in baseline mIPSC amplitude and frequency 
(*, p<.05, Student’s t test).   
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Figure 4.3.  Inhibition of calcium release from internal stores prevented 
ethanol from increasing mIPSC frequency. A, the ability of 100 mM ethanol 
(EtOH) to increase mIPSC frequency was prevented by 1 µM thapsigargin 
(thaps), 100 µM ryanodine (Ry), and 14 µM 2-APB (*, p<.05, one-way ANOVA, 
Dunnett’s post hoc test). B, a trace from a representative neuron showing the 
effect of 100 mM ethanol on mIPSC frequency in the presence of 1 µM 
thapsigargin. 
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Figure 4.4. GABAergic presynaptic terminals were immunopositive for IP3R. 
A, presynaptic terminals likely (because of their morphology) to be GABAergic (*, 
p<.05, Student’s t test), probable glutamatergic presynaptic terminals (*, p<.05, 
Student’s t test) and Purkinje cell spines (*, p<.05, Student’s t test) had 
significantly more IP3R staining compared to parallel fibers. B, a micrograph of a 
glutamatergic presynaptic terminal that is immunopositive for IP3R (top). An 
immunonegative glutamatergic terminal is visible below it. C, a micrograph of an 
immunopositive GABAergic terminal that synapses onto a Purkinje cell dendrite. 
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Chapter V: The Role of the Adenylate Cyclase/PKA pathway in 
Ethanol-enhanced GABA Release 
 
INTRODUCTION 
I provided evidence that calcium release from internal stores plays an 
essential role in ethanol-enhanced spontaneous GABA release at the cerebellar 
interneuron-Purkinje cell synapse; moreover, this ethanol action is not dependent 
on the influx of extracellular calcium.  However, the manner in which ethanol 
interacts with internal calcium stores is uncertain.  While internal stores release 
calcium through activation of the IP3Rs and RyRs, there is no current evidence 
suggesting that ethanol interacts directly with these receptors.  The amount of 
calcium released from the IP3Rs and RyRs is regulated by a number of factors, 
including calcium itself, nucleotides and protein kinases (Patterson et al., 2004; 
Bardo et al., 2006).  Therefore, one hypothesis is that ethanol indirectly 
modulates calcium release from internal stores to influence GABA release. 
In addition to internal calcium stores, ethanol-enhanced GABA release is 
altered by activation of GPCRs that are linked to Gαi and Gαs G proteins.  
Nociceptin, which is the endogenous ligand of a Gαi-coupled GPCR 
(nociceptin/orphanin FQ peptide receptor), blocks ethanol from enhancing GABA 
release in the central nucleus of the amygdala (Roberto and Siggins, 2006).  
Antagonists for the δ-opioid receptor and the GABAB receptor, both of which are 
Gαi-linked GPCRs, augment the ability of ethanol to increase GABA release in 
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the amygdala and hippocampus (Ariwodola and Weiner, 2004; Zhu and Lovinger, 
2006; Kang-Park et al., 2007).  Consistent with these results, activation of the 
CRF1 receptor, a GPCR coupled to Gαs, enhances the effect of ethanol on 
GABA release in the central nucleus of the amygdala (Nie et al., 2004).  These 
results suggest that a variety of Gαi/s-coupled GPCRs can regulate ethanol-
enhanced spontaneous GABA release.   
Both the Gαi and Gαs subunits modulate adenylate cyclase with Gαs 
activating adenylate cyclase and Gαi inhibiting it.  When adenylate cyclase is 
activated, it converts adenosine-5'-triphosphate (ATP) into 3'-5'-cyclic adenosine 
monophosphate (cAMP), which can bind to protein kinase A (PKA) regulatory 
subunits (Hanoune and Defer, 2001).  The binding of cAMP to PKA frees the 
PKA catalytic subunits from the regulatory subunits, allowing the catalytic 
subunits to phosphorylate nearby targets.  There are PKA phosphorylation sites 
on both the IP3R (Mignery et al., 1990; Patterson et al., 2004) and RyR (Sobie et 
al., 2006), and phosphorylation of these receptors leads to increased calcium 
release (Bugrim, 1999; Bardo et al., 2006).  In addition, PKA acts at the 
neurotransmitter release machinery to regulate synaptic transmission (Trudeau 
et al., 1996; Chheda et al., 2001; Seino and Shibasaki, 2005).  Therefore, 
activation of adenylate cyclase and PKA could be playing a role in the ethanol-
mediated increase in GABA release.  The present study will investigate the role 
of the adenylate cyclase/PKA pathway in ethanol-enhanced spontaneous GABA 
release as well as the role of PKA in GABAergic neurotransmission. 
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RESULTS 
Activation of Gαi-coupled GPCRs prevents ethanol from increasing mIPSC 
frequency.  Because of previous research that demonstrated a link between 
Gαi/s-coupled GPCRs and ethanol-enhanced GABA release in other brain 
regions (Ariwodola and Weiner, 2004; Nie et al., 2004; Roberto and Siggins, 
2006; Zhu and Lovinger, 2006; Kang-Park et al., 2007), it was determined 
whether this observation was also true at the interneuron-Purkinje cell synapse.  
Both GABAB receptors and cannabinoid 1 receptors are Gαi-coupled GPCRs 
located in the molecular layer of the cerebellum, and activation of either receptor 
inhibits baseline mIPSC frequency at this synapse (Takahashi and Linden, 2000; 
Harvey and Stephens, 2004; Yamasaki et al., 2006).  Similar to these results, 
application of a GABAB receptor agonist, baclofen (5 µM), or a cannabinoid 
receptor agonist, WIN 55,212-2 (WIN, 5 µM), caused a significant reduction in 
baseline mIPSC frequency (control: 2.3 ± 0.6 Hz, baclofen: 0.6 ± 0.2 Hz, n = 4; 
control: 2.9 ± 0.8 Hz, WIN: 1.1 ± 0.3 Hz, n = 13; Fig. 5.1A) with no significant 
effect on decay time or amplitude (data not shown).  A cumulative probability 
curve from a representative neuron demonstrating that 5 µM WIN shifts the 
interevent interval curve to the right, which is interpreted as WIN decreasing 
mIPSC frequency, is shown in Figure 5.1B.   In the presence of baclofen or WIN, 
the ability of ethanol to increase mIPSC frequency was significantly blocked 
(baclofen: 3.9 ± 7.1%, n = 5; WIN: -1.2 ± 3.4%, n = 8; Fig. 5.1C) compared to 
control (28.7 ± 3.4%, n = 12).  Shown in Figure 5.1D is a cumulative probability 
curve from a representative neuron showing that 5 µM WIN blocks 100 mM 
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ethanol from shifting the curve to the left.  Collectively, these data demonstrate 
that activation of the Gαi-coupled GPCR pathway reduces baseline spontaneous 
GABA release and prevents ethanol-enhanced spontaneous GABA release at 
the interneuron-Purkinje cell synapse. 
 
Tonic activation of GABAB receptors does not alter the ability of ethanol to 
increase mIPSC frequency and decrease the PPR.  Because activation of 
GABAB receptors with baclofen inhibited ethanol-enhanced spontaneous GABA 
release from the interneurons, I wanted to determine if tonic activation of GABAB 
receptors was masking the extent of the ethanol effect on both spontaneous and 
evoked GABA release.  First, it was determined if ethanol still increased mIPSC 
frequency to a similar extent in the presence of a GABAB receptor antagonist, 
CGP 52432 (10 µM).  Compared to control (-1.8 ± 0.8%, n = 6, Fig. 5.2A), 50 mM 
(7.1 ± 1.9%, n = 6) and 100 mM (22.7 ± 2.1%, n = 6) ethanol significantly 
increased mIPSC frequency in the presence of CGP 52432 to a similar extent to 
that seen in the absence of CGP 52432.  
To see if an effective concentration of CGP 52432 was used, the ability of 
CGP 52432 to antagonize the effect of baclofen on mIPSC frequency was 
determined.  The baclofen (5 µM) effect on mIPSC frequency (control: 2.5 ± 0.6 
Hz; baclofen: 1.2 ± 0.4 Hz, n = 6) was reversed in the presence of the GABAB 
receptor antagonist (CGP 52432 + baclofen: 2.4 ± 0.6 Hz, n = 6, Fig. 5.2B).  A 
trace from a representative neuron showing the effect of baclofen on mIPSC 
frequency and the ability of CGP 52432 to reverse this effect is shown in Figure 
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5.2C.  CGP 52432 (10 µM) significantly increased baseline mIPSC frequency 
(control: 1.6 ± 0.2 Hz; CGP 52432: 1.8 ± 0.3 Hz, n = 14, Fig. 5.2D), suggesting 
that there is tonic activation of GABAB receptors that affects spontaneous GABA 
release.  In the presence of CGP 52432, 100 mM ethanol significantly decreased 
the PPR (20.7 ± 3.1%, n = 10, Fig. 5.2E) to a similar extent to that seen in the 
absence of CGP 52432.  Overall, these results suggest that, despite tonic 
activation of GABAB receptors, antagonism of GABAB receptors does not alter 
the ability of ethanol to increase evoked and spontaneous GABA release. 
 
A cannabinoid receptor antagonist has opposite effects on the ethanol-
induced increase in mIPSC frequency and decrease in PPR.  Activation of 
cannabinoid receptors with WIN inhibited ethanol-enhanced spontaneous GABA 
release (Fig. 5.1C); therefore, I wanted to determine if tonic activation of 
cannabinoid receptors was masking the extent of the ethanol effect on both 
spontaneous and evoked GABA release.  First, it was determined if ethanol still 
increased mIPSC frequency to a similar extent in the presence of a cannabinoid 
receptor antagonist, AM-251 (5 µM).  In the presence of AM-251, 50 mM (15.3 ± 
3.4%, n = 7) and 100 mM (29.4 ± 7.1%, n = 7) ethanol significantly increased 
mIPSC frequency compared to control (0.9 ± 3.6%, n = 7, Fig. 5.3A) to a similar 
extent to that seen in the absence of AM-251.   
To document that this was an effective concentration of AM-251 (5 µM), 
the ability of AM-251 to block the cannabinoid agonist-induced decrease in 
mIPSC frequency was tested.  WIN (5 µM), significantly reduced (0.9 ± 0.2 Hz, n 
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= 6) mIPSC frequency compared to control (1.7 ± 0.2 Hz, n = 6), and 5 µM AM-
251 reversed this WIN effect (1.6 ± 0.3 Hz, n = 6, Fig. 5.3B).  AM-251 had no 
effect on baseline mIPSC frequency (control: 1.8 ± 0.2 Hz; AM-251: 2.0 ± 0.2 Hz, 
n = 13, Fig. 5.3C), suggesting that there is not tonic activation of cannabinoid 
receptors that affects spontaneous GABA release.  These results suggest that a 
cannabinoid receptor antagonist has no effect on spontaneous GABA release or 
on ethanol-enhanced spontaneous GABA release.  Interestingly, in the presence 
of AM-251, the ability of 100 mM ethanol to decrease the PPR was blocked (1.1 
± 4.3%, n = 8, Fig. 5.3E) and AM-251 significantly decreased the baseline PPR 
(44.4 ± 12.9%, n = 6, Fig. 5.3D).  These results demonstrate that there is tonic 
activation of cannabinoid receptors that affects evoked GABA release and that 
inhibition of cannabinoid receptors blocks ethanol-enhanced evoked GABA 
release. 
 
Inhibition of adenylate cyclase or PKA blocks ethanol from increasing 
mIPSC frequency.  Next it was determined if inhibiting adenylate cyclase and 
PKA, the intracellular messengers downstream of the Gαi-coupled GPCRs, could 
prevent ethanol from increasing spontaneous GABA release.   To assess the role 
of adenylate cyclase in this ethanol mechanism, two different purine site 
inhibitors (SQ 22,536 and DDA) were used that inhibit all isoforms of adenylate 
cyclase (Dessauer et al., 1999).  As shown in Figure 5.4A, the ability of ethanol 
to increase mIPSC frequency was significantly reduced in the presence of 300 
µM SQ 22,536 (15.0 ± 3.6%, n = 10) and 10 µM DDA (12.4 ± 2.3%, n = 9) 
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compared to control.  SQ 22,536 inhibits the norepinephrine-induced increase in 
mIPSC frequency at the interneuron-Purkinje cell synapse (Harvey and 
Stephens, 2004), which is an effect mediated by activation of Gαs-coupled 
GPCRs.  Similar to these results, 10 µM norepinephrine caused a 103 ± 11.8% 
(n = 5) increase in mIPSC frequency, while in the presence of 300 µM SQ 22,536 
the norepinephrine effect was significantly reduced to 15.0 ± 5.8% (n = 3, p<05, 
Student’s t-test).  Therefore, an effective concentration of SQ 22,536 was used in 
these experiments.  These results suggest that adenylate cyclase is involved in 
ethanol-enhanced spontaneous GABA release. 
To determine the role of PKA in ethanol-enhanced GABA release, two 
PKA antagonists, H-89 and Rp-cAMP, were used that have different mechanisms 
of action.  H-89 acts at the PKA ATP-binding site, while Rp-cAMP binds to the 
cAMP binding sites to prevent the regulatory subunits from dissociating from the 
catalytic subunits (Lochner and Moolman, 2006).  Both 10 µM H-89 and 10 µM 
Rp-cAMP significantly reduced the ability of ethanol to increase mIPSC 
frequency (8.2 ± 2.1%, n = 7 and 1.4 ± 2.5%, n = 10, respectively, Fig. 5.4A) 
compared to control.  A trace from a representative neuron showing the effect of 
ethanol on mIPSC frequency in the presence of 10 µM Rp-cAMP is shown in 
Figure 5.4B.  A lower Rp-cAMP concentration (1 µM) did not prevent ethanol 
from increasing mIPSC frequency (22.5 ± 8.2%, n = 3).  A higher concentration of 
H-89 was not tested because of known nonspecific effects that can start to occur 
at even 10 µM (Lochner and Moolman, 2006).  Overall, these results suggest that 
PKA plays an important role in ethanol-enhanced spontaneous GABA release. 
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To determine if the PKA antagonists were acting at the presynaptic 
terminal and not the postsynaptic neuron, the membrane impermeable PKA 
antagonist, PKI, was included in the pipette internal solution, which limits the 
PKA antagonist to the postsynaptic neuron.  With 5 µM PKI in the pipette internal 
solution, both 50 (14.6 ± 2.8%, n = 8) and 100 mM (27.1 ± 9.2%, n = 6) ethanol 
significantly increased mIPSC frequency compared to control (-1.3 ± 1.6%, n = 8, 
Fig. 5.4C).  A cumulative probability curve from a representative neuron shows 
that 100 mM ethanol still shifts the distribution of the interevent interval curve to 
the left with 5 µM PKI in the pipette internal solution (Fig. 5.4D).  Because there 
was no PKI effect, there was concern that PKI was not reaching the postsynaptic 
neuron; however, PKI blocked the effect of a PKA agonist in a separate 
experiment (see Fig. 5.6A).  These results suggest that the PKA antagonist is 
acting presynaptically to inhibit ethanol-enhanced spontaneous GABA release. 
 
Cannabinoids and ethanol act through similar downstream messengers to 
alter mIPSC frequency.  A CB1 receptor agonist decreases spontaneous GABA 
release at the interneuron-Purkinje cell synapse (Fig. 5.1A), and this effect 
involves calcium release from RyRs (Yamasaki et al., 2006).  Therefore, it was 
determined if the downstream messengers shown to play a role in the ethanol-
induced increase in spontaneous GABA release also play a role in the 
cannabinoid-induced decrease in spontaneous GABA release.  To confirm the 
involvement of internal calcium stores, the thapsigargin protocol described in 
Chapter 4 was used.  Compared to control (58.4 ± 3.0%, n = 13), 1 µM 
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thapsigargin significantly prevented WIN from decreasing mIPSC frequency (21.7 
± 7.7%, n = 7, Fig. 5.5A).  The high potassium (15 mM) extracellular solution in 
the absence of thapsigargin had no effect on the ability of WIN to decrease 
mIPSC frequency (55.8 ± 5.5%, n = 5, Fig. 5A).  The IP3R antagonist, 2-APB (14 
µM), significantly reduced the ability of WIN to decrease mIPSC frequency (31.5 
± 6.3%, n = 8, Fig. 5.5A).  As mentioned above, a similar effect has been shown 
with a RyR antagonist (Yamasaki et al., 2006).  The voltage dependent calcium 
channel inhibitor, CdCl2 (50 µM), did not significantly prevent WIN from 
decreasing mIPSC frequency (43.3 ± 6.9%, n = 8, Fig. 5.5A).  In addition, 
inclusion of 30 mM BAPTA in the pipette internal solution, which limits BAPTA to 
the postsynaptic neuron, was ineffective at blocking WIN (46.4 ± 3.8%, n = 8, Fig. 
5A).  Overall, these results suggest that the mechanism of the cannabinoid 
agonist-mediated decrease in mIPSC frequency is a presynaptic, calcium-
dependent process that most likely involves calcium release from internal stores 
with minimal involvement (if any at all) from the voltage dependent calcium 
channels.   
Next the role of PKA in the cannabinoid-induced decrease in mIPSC 
frequency was determined.  The ability of WIN to decrease mIPSC frequency 
was significantly reduced in the presence of the PKA agonist dBcAMP (100 µM: 
37.1 ± 4.4%, n = 7; 300 µM: 31 ± 9.3%, n = 7; Fig. 5.5B) compared to control, but 
there was no effect at 30 µM dBcAMP (48.3 ± 8.0%, n = 6).  There was a 
significant linear trend across concentrations for the effect of the PKA agonist on 
the WIN-induced decrease in mIPSC frequency (n = 7, r = -0.53, p<.05), which 
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suggests that dBcAMP inhibits WIN from decreasing spontaneous GABA release 
in a dose-dependent manner.   
 
Activation of PKA affects baseline mIPSC properties.  At 30 and 100 µM 
dBcAMP, there was a significant decrease in baseline mIPSC amplitude (30 µM: 
21.6 ± 4.5%, n = 7; 100 µM: 18.0 ± 7.4%, n = 7) with no change in baseline 
mIPSC τ-slow (Fig. 5.6A).   At 300 µM dBcAMP, there was a significant decrease 
in baseline mIPSC amplitude (32 ± 2.9%, n = 6. Fig. 5.6A) and increase in 
baseline mIPSC slow decay time (33.7 ± 9.4%, n = 6).  A trace from 
representative neuron showing that 300 µM dBcAMP increases mIPSC slow 
decay time and decreases mIPSC amplitude is shown in Figure 5.6Ba.  There 
was no effect on baseline mIPSC frequency or on baseline mIPSC fast decay 
time at any dBcAMP concentration (data not shown).   
The change in mIPSC slow decay time and amplitude appears to be due 
to a postsynaptic PKA mechanism because inclusion of 5 µM PKI in the internal 
solution blocked 300 µM dBcAMP from increasing mIPSC slow decay time (-1.0 
± 4.4%, n = 7) and decreasing mIPSC amplitude (2.3 ± 4.9%, n = 7, Fig. 5.6A).  
A trace from a representative neuron showing this PKI effect is in Figure 5.6Bb.  
These results suggest that the PKA agonist is having a PKA-dependent, 
postsynaptic effect that is manifested through a change in mIPSC slow decay 
time and amplitude. 
Based on the above results, it appeared as if a PKA agonist did not 
increase spontaneous GABA release.  While I was initially hesitant to try higher 
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concentrations of the PKA agonist, dBcAMP, there are reports that higher 
concentrations of the PKA agonist could increase mIPSC frequency (Kano and 
Konnerth, 1992; Kondo and Marty, 1997); therefore, a higher concentration of 
dBcAMP was tested.  At 1 mM dBcAMP, there was a significant increase in 
mIPSC frequency (control: 1.3 ± 0.1 Hz, dBcAMP: 2.0 ± 0.2 Hz, n = 8, Fig. 5.6C).  
Consistent with the results seen at lower dBcAMP concentrations, there was also 
an increase in mIPSC slow decay time (control: 13.2 ± 0.8 ms, dBcAMP: 24.1 ± 
4.8 ms, Fig. 5.6C) and a decrease in mIPSC amplitude (control: 24 ± 1.2 pA, 
dBcAMP: 19.8 ± 1.3 pA, Fig. 5.6C).  These results suggest that a PKA agonist 
has both presynaptic and postsynaptic effects at the GABAergic synapse. 
 
Buffering presynaptic calcium prevents a PKA antagonist from decreasing 
baseline mIPSC frequency.  Because of the established role of PKA in 
neurotransmitter release (Trudeau et al., 1996; Chheda et al., 2001; Seino and 
Shibasaki, 2005), the effect of a PKA antagonist on baseline mIPSC frequency 
was tested.  Both 10 µM and 25 µM Rp-cAMP significantly decreased mIPSC 
frequency (by 23.3 ± 6.8%, n = 7 and 31.2 ± 3.6%, n = 11, respectively), while 1 
µM Rp-cAMP was without effect (0.6 ± 4.8%, n = 4, Fig. 5.7A).  At these 
concentrations of Rp-cAMP, no changes in mIPSC decay time or amplitude were 
observed (data not shown).  In Figure 5.7B a cumulative probability curve from a 
representative neuron demonstrates that 25 µM Rp-cAMP shifts the distribution 
of the interevent interval curve to the right, which is interpreted as Rp-cAMP 
decreasing mIPSC frequency.  At 100 µM Rp-cAMP there was a significant 
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decrease in mIPSC frequency (78.9 ± 8.3%, n = 3), but there was also a 
significant decrease in mIPSC amplitude (29.3 ± 3.9%), making it difficult to 
conclude whether a presynaptic and/or postsynaptic mechanism was responsible 
for this change.  These results suggest that presynaptic activation of PKA plays a 
role in the generation of spontaneous GABA release.    
Because of the role of calcium and PKA in the ethanol and cannabinoid-
induced change in spontaneous GABA release, I determined whether there is a 
link between PKA, calcium, and spontaneous GABA release.  In the presence of 
BAPTA-AM, a membrane permeable calcium chelator, the ability of 25 µM Rp-
cAMP to decrease mIPSC frequency was significantly reduced (5.9 ± 2.5%, n = 
8, Fig. 5.7C) compared to control.  A cumulative probability curve from a 
representative neuron shows that 100 µM BAPTA-AM prevents 25 µM Rp-cAMP 
from shifting the curve (Fig. 5.7D).  Addition of 30 mM BAPTA to the pipette 
internal solution did not prevent Rp-cAMP from decreasing mIPSC frequency 
(31.8 ± 3.8%, n = 7, Fig. 5.7C).  These results suggest that changes in 
presynaptic calcium are required for a PKA antagonist to decrease mIPSC 
frequency.  Thapsigargin was also able to significantly block 25 µM Rp-cAMP 
from decreasing mIPSC frequency (10.7 ± 5.6%, n = 6), suggesting that this Rp-
cAMP mechanism involves calcium release from internal stores.  However, the 
high potassium solution protocol also blocked the PKA antagonist effect (-2.1 ± 
2.6%, n = 3).  Therefore, the role of internal calcium stores in the PKA 
antagonist-mediated suppression of spontaneous GABA release is inconclusive. 
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DISCUSSION 
The Gαi-coupled GPCR agonists, WIN and baclofen, blocked ethanol from 
increasing spontaneous GABA release at the interneuron-Purkinje cell synapse.  
Consistent with these results, it has been presented recently that WIN inhibits 
ethanol-enhanced GABA release in the basolateral and central nucleus of the 
amygdala (Roberto et al., 2008; Talani and Lovinger, 2008).  Similarly, baclofen 
prevents ethanol from increasing action potential-dependent GABA release in the 
hippocampus (Ariwodola and Weiner, 2004). However, in the VTA baclofen does 
not inhibit ethanol from increasing action potential-dependent GABA release, 
despite the fact that baclofen affects action potential-dependent GABA release 
(Theile et al., 2008).   
Because activation of Gαi-linked GPCRs blocked ethanol from increasing 
spontaneous GABA release onto cerebellar Purkinje cells, I tested if tonic 
activation of Gαi-coupled GPCRs was preventing ethanol from fully eliciting 
GABA release at the interneuron-Purkinje cell synapse.   Despite tonic activation 
of the GABAB receptors, a GABAB receptor antagonist did not enhance the ability 
of ethanol to increase mIPSC frequency or decrease the PPR at the interneuron-
Purkinje cell synapse.  Similar results are seen in the VTA (Theile et al., 2008); 
however, a GABAB receptor antagonist enhances the ability of ethanol to 
increase GABA release onto basolateral amygdala neurons and CA1 
hippocampal neurons (Ariwodola and Weiner, 2004; Zhu and Lovinger, 2006).  
Overall, these variable results suggest that the ability of the GABAB receptor 
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agonist and antagonist to affect ethanol-enhanced spontaneous GABA release is 
brain region-specific.   
There was not tonic activation of the cannabinoid receptors that affected 
spontaneous GABA release, and consistent with this, a cannabinoid receptor 
antagonist had no effect on the ethanol-induced increase in spontaneous GABA 
release.  There was tonic activation of cannabinoid receptors that decreased 
evoked GABA release, and a cannabinoid receptor antagonist actually blocked 
the ability of ethanol to increase evoked GABA release.  This result was 
unexpected considering that a cannabinoid receptor agonist blocks ethanol-
enhanced spontaneous GABA release.  Because mGluR1 activation on Purkinje 
cells can induce endocannabinoid release from the Purkinje cell (for review see 
Hashimotodani et al., 2007), I hypothesized that the lack of ethanol effect in the 
presence of the CB receptor antagonist was due to a mGluR1-mediated effect.  
However, in the presence of a mGluR1 antagonist (JNJ 16259685, 20 µM) and a 
cannabinoid receptor antagonist, ethanol still did not increase evoked GABA 
release (n = 3, data not shown).  Another hypothesis is the cannabinoid receptor 
antagonist increases the amount of evoked glutamate release (in addition to 
GABA release), which could activate presynaptic group II mGluRs that are not 
normally activated in the absence of the cannabinoid receptor antagonist.  Like 
the GABAB receptors and cannabinoid receptors, the mGluRs are Gαi-linked 
GPCRs that inhibit GABA release at the interneuron-Purkinje cell synapse 
(Raiteri, 2008).  Therefore, I predict that activation of group II mGluRs due to the 
presence of the cannabinoid receptor antagonist inhibits ethanol-enhanced 
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evoked GABA release.  This possibility will be tested in the future by combining a 
group II mGluR antagonist with the cannabinoid receptor antagonist and 
determining if ethanol can increase evoked GABA release in these conditions.     
Adenylate cyclase and PKA, which are downstream messengers of the 
Gαi/s–coupled GPCRs, contribute an essential part to ethanol-enhanced 
spontaneous GABA release.  Because a membrane impermeable PKA 
antagonist in the pipette internal solution did not prevent ethanol from increasing 
spontaneous GABA release, this PKA effect is occurring presynaptically.  There 
is considerable evidence connecting the adenylate cyclase/PKA pathway to the 
effects of ethanol (Pandey, 1998; Newton and Messing, 2006).  Adenylate 
cyclase isoforms 1,7 and 8 have all been linked to ethanol with biochemical, 
electrophysiological and behavioral studies in transgenic mice (Hanoune and 
Defer, 2001; Maas et al., 2005).  Through a PKA dependent mechanism, an in 
vivo ethanol exposure induces a long-lasting potentiation of GABAergic synapses 
in the VTA (Melis et al., 2002).  The adenosine A2 receptor, which leads to 
increased activation of the adenylate cyclase/PKA pathway, mediates important 
ethanol effects (Mailliard and Diamond, 2004).  At the behavioral level, a 
reduction in PKA signaling affects alcohol consumption and the sensitivity to the 
sedative effects of alcohol (Thiele et al., 2000; Wand et al., 2001; Fee et al., 
2006; Misra and Pandey, 2006; Lai et al., 2007).  Therefore, the adenylate 
cyclase/PKA pathway plays an important role in multiple alcohol actions 
extending from molecular to behavioral.  
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To learn more about the mechanism behind the ethanol-induced increase 
in GABA release, I studied the mechanism responsible for the WIN-induced 
decrease in GABA release.  Previously it was shown that calcium release from 
RyRs plays a role in this cannabinoid mechanism (Yamasaki et al., 2006).  The 
present work confirmed the involvement of internal calcium stores in the 
cannabinoid-induced decrease in GABA release and illustrated that calcium 
release from IP3Rs is involved.  Voltage dependent calcium channels did not play 
a significant role in the cannabinoid-mediated suppression of spontaneous GABA 
release at this synapse; a similar conclusion was made previously based on data 
showing that CdCl2 has no significant effect on baseline mIPSC frequency 
(Takahashi and Linden, 2000).  Additionally, including BAPTA in the internal 
solution did not significantly block the cannabinoid-induced decrease in 
spontaneous GABA release, which supports the idea that the calcium-dependent 
portion of this cannabinoid mechanism is occurring presynaptically.   
A PKA agonist was used to determine the role of PKA in the cannabinoid-
mediated suppression of spontaneous GABA release.  The PKA agonist, 
dBcAMP, dose-dependently reduced the ability of WIN to decrease mIPSC 
frequency, which suggests that the ability of the cannabinoid agonist to decrease 
spontaneous GABA release involves inhibition of PKA.  This result is consistent 
with activation of Gαi-coupled GPCRs leading to reduced activation of PKA, and 
data showing that a PKA antagonist decreases spontaneous GABA release (Fig. 
5.7A; Jeong et al., 2003; Lee et al., 2008).  Overall, these results suggest that 
internal calcium stores and PKA are playing an important role in the CB-mediated 
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decrease in spontaneous GABA release, as has been shown for the mechanism 
of ethanol-enhanced spontaneous GABA release.     
I determined if a PKA agonist had an effect on GABAergic 
neurotransmission.  Interestingly, during the application of 300 µM dBcAMP 
baseline mIPSC slow decay time and amplitude were increased and decreased, 
respectively.  Both deceases and increases in mIPSC amplitude have been 
reported after application of PKA and PKA agonists (Kano and Konnerth, 1992; 
Nusser et al., 1999; Poisbeau et al., 1999).  A possible reason for this 
discrepancy is differences in GABAA receptor subunit composition and in GABAA 
receptor associated proteins (Nusser et al., 1999).  Regardless, this effect 
appears to be a postsynaptic, PKA specific action because the dBcAMP effect 
was blocked when a membrane impermeable PKA antagonist was included in 
the pipette internal solution.  At a higher concentration of the PKA agonist (1 
mM), there was the same increase and decrease in mIPSC slow decay time and 
amplitude, respectively.  However, there also was an increase in mIPSC 
frequency, which is consistent with other studies using this high concentration 
(Kano and Konnerth, 1992; Kondo Marty, 1997).  Possible explanations for the 
necessity of a high dBcAMP concentration to increase spontaneous GABA 
release include low cell permeability of dBcAMP at the presynaptic terminal 
and/or degradation of dBcAMP by phosphodiesterases.   
The PKA antagonist, Rp-cAMP (10 µM and 25 µM), inhibited baseline 
spontaneous GABA release, which is consistent with similar studies conducted in 
the hippocampus and hypothalamus (Jeong et al., 2003; Lee et al., 2008).  There 
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was no PKA antagonist effect in the tuberomammillary nucleus, but this could be 
due to the low PKA antagonist concentration used in this study (Yum et al., 
2008).  At 1 µM Rp-cAMP, there was no effect on baseline spontaneous GABA 
release or on ethanol-enhanced spontaneous GABA release.  These results 
suggest that the concentration of the PKA antagonist must be high enough to 
decrease baseline spontaneous GABA release if the antagonist is going to be 
effective at reducing ethanol-enhanced spontaneous GABA release.  
Incubating slices with BAPTA-AM blocked Rp-cAMP from decreasing 
mIPSC frequency, suggesting that the ability of a PKA antagonist to decrease 
spontaneous GABA release involves a calcium-dependent mechanism.  When 
BAPTA was limited to the postsynaptic neuron, Rp-cAMP still decreased GABA 
release.  These results suggest that a presynaptic, calcium-dependent 
mechanism is responsible for the PKA antagonist-mediated decrease in 
spontaneous GABA release.  Two possible calcium-dependent mechanisms 
related to PKA involve PKA phosphorylating the IP3R and RyR to increase 
calcium release from internal stores (Mignery et al., 1990; Bugrim, 1999; 
Patterson et al., 2004; Bardo et al., 2006; Sobie et al., 2006) and/or PKA 
phosphorylating a protein in the neurotransmitter release machinery that is 
involved in calcium dependent exocytosis (Trudeau et al., 1996; Chheda et al., 
2001).   
I attempted to determine if internal calcium stores are involved in the Rp-
cAMP-mediated suppression of spontaneous GABA release.  Even though the 
thapsigargin protocol was successful at blocking the PKA antagonist effect, the 
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results are not interpretable because the high potassium solution protocol had 
the same effect.  One possible explanation is that the presynaptic depolarization 
induced by the high potassium solution altered the phosphorylation state of 
proteins that are normally affected by the PKA antagonist.  Therefore, the role of 
internal calcium stores in the PKA antagonist-induced decrease in spontaneous 
GABA release is unknown.  However, cAMP-dependent GABA release occurs in 
the absence of extracellular calcium (Kondo and Marty, 1997), which suggests 
the possibility that PKA-mediated changes in spontaneous GABA release are not 
dependent on the influx of extracellular calcium.   
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Figure 5.1.  WIN 55,212-2 and baclofen decreased baseline mIPSC 
frequency and prevented ethanol from increasing mIPSC frequency. A, WIN 
55,212-2 (WIN, 5 µM) and baclofen (5 µM) reduced baseline mIPSC frequency 
(*, p<.05, paired Student’s t test). B, a cumulative frequency histogram showing 
the effect of 5 µM WIN on the interevent interval curve. C, WIN and baclofen 
prevented 100 mM ethanol (EtOH) from increasing mIPSC frequency (*, p<.05, 
one-way ANOVA, Dunnett’s post hoc test). D, a cumulative frequency histogram 
from a representative neuron demonstrating the effect of 100 mM ethanol on the 
interevent interval curve in the presence of WIN.    
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Figure 5.2.  A GABAB receptor antagonist did not affect the ethanol-induced 
increase in mIPSC frequency or decrease in PPR. A, CGP 52432 (CGP, 10 
µM) did not alter the ability of 50 and 100 mM ethanol to increase mIPSC 
frequency (*, p<.05, one-way ANOVA, Dunnett’s post hoc test). B, the reduction 
in mIPSC frequency by baclofen (5 µM) was reversed by CGP (*, p<.05, paired 
Student’s t test). C, a trace from a representative neuron showing the effect of 
baclofen on mIPSC frequency and the ability of CGP to reverse it. D, CGP 
increased baseline mIPSC frequency (*, p<.05, paired Student’s t test). E, CGP 
did not affect the ability of 100 mM ethanol to decrease the PPR (*, p<.05, paired 
Student’s t test).    
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Figure 5.3.  A cannabinoid receptor antagonist had no effect on the 
ethanol-induced increase in mIPSC frequency but blocked the ethanol-
induced decrease in PPR. A, AM-251 (5 µM) did not alter the ability of 50 and 
100 mM ethanol (EtOH) to increase mIPSC frequency (*, p<.05, one-way 
ANOVA, Dunnett’s post hoc test). B, the reduction in mIPSC frequency by WIN 
(5 µM) was reversed by AM-251 (*, p<.05, paired Student’s t test). C, AM-251 
had no effect on baseline mIPSC frequency. D, AM-251 significantly decreased 
the PPR (*, p<.05, paired Student’s t test). E, AM-251 blocked the ability of 100 
mM ethanol to decrease the PPR (*, p<.05, paired Student’s t test).    
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Figure 5.4.  Adenylate cyclase and protein kinase A (PKA) antagonists 
prevented ethanol from increasing mIPSC frequency. A, SQ 22,536 (SQ, 300 
µM), DDA (10 µM), H-89 (10 µM) and Rp-cAMP (Rp, 10 µM) prevented 100 mM 
ethanol (EtOH) from increasing mIPSC frequency (*, p<.05, one-way ANOVA, 
Dunnett’s post hoc test). B, a trace from a representative neuron demonstrating 
the effect of 100 mM ethanol on mIPSC frequency in the presence of Rp-cAMP. 
C, ethanol (50 and 100 mM) increased mIPSC frequency when 5 µM PKI was in 
the pipette internal solution (*, p<.05, one-way ANOVA, Dunnett’s post hoc test). 
D, a cumulative frequency histogram from a representative neuron demonstrating 
the effect of ethanol on the interevent interval curve with PKI in the pipette 
internal solution.  
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Figure 5.5.  Inhibition of calcium release from internal stores and activation 
of PKA prevented WIN 55,212-2 from decreasing mIPSC frequency. A, 
thapsigargin (Thaps, 1 µM) and 2-APB (14 µM) inhibited WIN 55,212-2 (WIN, 5 
µM) from decreasing mIPSC frequency, while the high potassium extracellular 
solution control (K+ soln, 15 mM), cadmium chloride (CdCl2, 50 µM), and BAPTA 
in the pipette internal solution (BAPTAint, 30 mM) were without effect (*, p<.05, 
one-way ANOVA, Dunnett’s post hoc test). B, the ability of WIN to decrease 
mIPSC frequency was significantly reduced in the presence of 100 µM and 300 
µM dBcAMP, while there was not a significant effect at 30 µM (*, p<.05, one-way 
ANOVA, Dunnett’s post hoc test).   
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Figure 5.6.  Activation of PKA affected baseline mIPSC properties. A, 
baseline mIPSC slow decay time (τ-slow) was increased in the presence of 300 
µM dBcAMP, and 30, 100 and 300 µM dBcAMP decreased baseline mIPSC 
amplitude (*, p<.05, paired Student’s t test). The effect of 300 µM dBcAMP on 
mIPSC τ-slow and amplitude was blocked when 5 µM PKI was included in the 
pipette internal solution. B, a trace from a representative neuron showing the 
effect of 300 µM dBcAMP on mIPSC τ-slow and amplitude (a) and the ability of 5 
µM PKI in the pipette internal solution to block this effect (b). C, 1 mM dBcAMP 
increased baseline mIPSC frequency, increased baseline mIPSC τ-slow and 
decreased baseline mIPSC amplitude (*, p<.05, paired Student’s t test).  
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Figure 5.7.  BAPTA-AM prevented Rp-cAMP from decreasing mIPSC 
frequency. A, Rp-cAMP (10 and 25 µM) significantly reduced baseline mIPSC 
frequency, while 1 µM Rp-cAMP was without effect (*, p<.05, paired Student’s t 
test). B, a cumulative frequency histogram from a representative neuron 
demonstrating the effect of 25 µM Rp-cAMP on the interevent interval curve. C, 
pre-incubation of the slice with BAPTA-AM (BAP-AM, 100 µM) decreased the 
effect of 25 µM Rp-cAMP on mIPSC frequency, while BAPTA in the internal 
solution (BAPTAint, 30 mM) did not have an effect (*, p<.05, one-way ANOVA, 
Dunnett’s post hoc test). D, a cumulative frequency histogram from a 
representative neuron demonstrating the effect of 25 µM Rp-cAMP on the 
interevent interval curve in the presence of 100 µM BAPTA-AM. 
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Chapter VI: The Role of the PLC/PKC Pathway in  
Ethanol-enhanced GABA Release 
 
INTRODUCTION 
I have provided evidence that calcium release from internal stores and the 
adenylate cyclase/PKA pathway play an essential role in ethanol-enhanced 
spontaneous GABA release at the cerebellar interneuron-Purkinje cell synapse.  
Calcium is released from internal stores through activation of the IP3Rs and 
RyRs.  The RyR is activated by calcium alone, while the IP3R also requires IP3 
(Berridge, 1998; Berridge et al., 2003).  This IP3 can come from activation of 
phospholipase C (PLC), which catalyzes the conversion of phosphoinositol 4,5-
bisphosphate into diacylglycerol (DAG) and IP3 (Kiselyov et al., 2003).   
The released calcium from activation of the IP3R and DAG contribute to 
the activation of typical PKC isoforms.  When PKC is in the inactive state, a 
pseudosubstrate within the regulatory domain is bound to the catalytic domain 
(House and Kemp, 1987).    When DAG binds to the PKC C1 domain and two 
cofactors, calcium and phosphatidylserine, bind to the C2 domain, there is a 
conformational change that frees the pseudosubstrate domain from the catalytic 
domain (Kishimoto et al., 1980; Boni and Rando, 1985; Ono et al., 1989; Bell and 
Burns, 1991).  In addition to the dissociation of the regulatory domain from the 
catalytic domain, phosphorylation and translocation to the appropriate subcellular 
location are necessary for PKC activation (Dutil et al., 1998; Le Good et al., 
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1998; Mochly-Rosen and Gordon, 1998).  Once PKC is activated, it can 
phosphorylate a number of substrates, including the IP3R (Patterson et al. 2004).  
Phosphorylation of the IP3R increases the amount of calcium released from the 
internal stores (Mignery et al. 1990; Bugrim 1999; Bardo et al. 2006), forming a 
calcium-mediated feedback loop between activation of the IP3R and PKC.  
There is no evidence supporting that ethanol binds directly to the IP3Rs 
and RyRs, with the more likely alternative being that ethanol indirectly modulates 
calcium release from internal stores.  Therefore, activation of PLC and PKC 
could be playing a role in the ethanol-mediated increase in GABA release.  The 
present study investigates the role of PLC and PKC in ethanol-enhanced 
spontaneous GABA release and determines the role of PKC in GABAergic 
neurotransmission. 
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RESULTS 
Inhibition of PLC or PKC prevents ethanol from increasing mIPSC 
frequency.  In the presence of the phosphoinositol (PI)-specific PLC antagonist, 
edelfosine (10 µM), the ability of ethanol to increase mIPSC frequency was 
significantly blocked (8.4 ± 4.1%, n = 9, Fig. 6.1A) compared to control (28.7 ± 
3.4%, n = 12, Fig. 6.1A).  A trace from a representative neuron showing that 10 
µM edelfosine blocks ethanol from increasing mIPSC frequency is shown in Fig. 
6.1B.  In addition, a PKC general antagonist, chelerythrine (1 µM) or a PKCε-
specific antagonist, εV1-2 (0.5 µM), prevented ethanol from increasing mIPSC 
frequency (chelerythrine: 7.2 ± 4.8%, n = 8; εV1-2: 9.1 ± 2.9%, n = 8, Fig. 6.1A).  
These results suggest that both PLC and PKC play a role in ethanol-enhanced 
spontaneous GABA release. 
To determine if the PKC antagonists were acting at the presynaptic 
terminal and not the postsynaptic neuron, the membrane impermeable PKC 
antagonist, PKC(19-36), was included in the pipette internal solution, which limits 
exposure to the PKC antagonist to the postsynaptic neuron.  With 20 µM 
PKC(19-36)
 
in the pipette internal solution, both 50 (18.9 ± 4.4%, n = 6) and 100 
mM (26.3 ± 3.4%, n = 6) ethanol significantly increased mIPSC frequency 
compared to control (0.7 ± 2.0%, n = 6, Fig. 6.1C).  A trace from a representative 
neuron showing the effect of ethanol on mIPSC frequency with 20 µM PKC(19-
36)
 
in the pipette internal solution is shown in Fig. 6.1D.  These results suggest 
that the PKC antagonist is acting presynaptically to block ethanol-enhanced 
spontaneous GABA release. 
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PKC antagonists affect baseline mIPSC properties.  The general PKC 
antagonist, chelerythrine (1 µM and 10 µM) did not have an effect on baseline 
mIPSC frequency, fast decay time and amplitude (Fig. 6.2A, B, and D).  There 
was an effect of 10 µM chelerythrine on mIPSC slow decay time (control: 12.8 ± 
0.7 Hz, chelerythrine: 14.0 ± 0.7 Hz, n = 5, Fig. 6.2B).  While a lower 
concentration of εV1-2 (0.5 µM) had no effect on mIPSC frequency, a higher 
concentration of εV1-2 (5 µM) increased mIPSC frequency (control: 2.5 ± 0.6 Hz, 
εV1-2: 3.1 ± 0.5 Hz, n = 5, Fig. 6.2A).  Interestingly, 0.5 µM εV1-2 significantly 
increased mIPSC fast decay time (control: 9.2 ± 0.3 Hz, εV1-2: 10.6 ± 0.5 Hz, n = 
14, Fig. 6.2B) and decreased mIPSC amplitude (control: 28.1 ± 2.0 Hz, εV1-2: 
19.1 ± 1.4 Hz, n = 5, Fig. 6.2D), while there was no effect on these mIPSC 
parameters at 5 µM εV1-2.  Overall, these results suggest that the general PKC 
antagonist and PKCε specific antagonist have differing effects on GABAergic 
neurotransmission.   
 
PKC agonists affect baseline mIPSC properties.  To further investigate the 
role of PKC in generating spontaneous GABA release, the effect of two PKC 
agonists, PMA and SC9, on GABAergic neurotransmission was determined.  
These two PKC agonists have different mechanisms of action: PMA activates 
PKC by binding to the C1 domain, while SC9 binds to the C2 domain (Ito et al., 
1986; Ono et al., 1989).  Both 3 µM PMA (control: 2.7 ± 0.5 Hz, PMA: 4.2 ± 0.7 
Hz, n = 7) and 10 µM PMA (control: 2.7 ± 0.7 Hz, PMA: 4.4 ± 0.9 Hz, n = 7) 
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significantly increased mIPSC frequency (Fig. 6.3A).  Likewise, both 25 µM SC9 
(control: 1.8 ± 0.3 Hz, SC9: 2.1 ± 0.4 Hz, n = 8) and 100 µM SC9 (control: 2.1 ± 
0.5 Hz, SC9: 2.6 ± 0.5 Hz, n = 9) significantly increased mIPSC frequency (Fig. 
6.3A).  There was no effect of any PKC agonist concentration on mIPSC slow 
decay time, but 25 µM SC9 (control: 9.4 ± 0.5 Hz, SC9: 10.1 ± 0.4 Hz, n = 8, Fig. 
6.3B) significantly increased mIPSC fast decay time.  There was also a reduction 
in mIPSC amplitude at 10 µM PMA (control: 25.1 ± 3.5 pA, PMA: 19.4 ± 2.3 pA, n 
= 7, Fig. 6.3D).  Overall, these results suggest that PKC agonists affect 
GABAergic neurotransmission, including spontaneous GABA release.   
 
Activation of PKA and PKC is necessary for ethanol to increase mIPSC 
frequency and cross-talk is not occurring between PKA and PKC.  To 
determine if there is cross-talk occurring between PKA and PKC in the 
mechanism of ethanol-enhanced spontaneous GABA release, I determined if a 
PKC agonist could reverse the effect of a PKA antagonist on ethanol-enhanced 
spontaneous GABA release, and vice versa.  As a control, the effect of a PKC 
agonist and a PKA agonist on ethanol-enhanced spontaneous GABA release 
was investigated.  Interestingly, both the PKA agonist and PKC agonist 
significantly blocked ethanol from increasing spontaneous GABA release 
compared to control (100 µM dBcAMP: 12.9 ± 2.3%, n = 5; 300 µM dBcAMP: 5.9 
± 2.5%, n = 9; 25 µM SC9: 0.8 ± 3.8%, n = 7; Fig. 6.4A).  A representative 
neuron demonstrating that 300 µM dBcAMP blocks ethanol from increasing 
mIPSC frequency is shown in Figure 6.4B.  Because PKA and PKC agonists and 
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antagonists blocked the ethanol effect, I was not able to conduct the cross-talk 
experiments. 
 As an alternative, I determined if the PKC and PKA agonist-induced 
increase in mIPSC frequency could be blocked with a PKA and PKC antagonist, 
respectively.  The effect of the PKC agonist, SC9 (25 µM), on mIPSC frequency 
(17.7 ± 5.5%, n = 8, Fig. 6.4C) was not reversed in the presence of the PKA 
antagonist, Rp-cAMP (25 µM, 17.6 ± 3.2%, n = 6).  Similarly, the effect of the 
PKA agonist, dBcAMP (1mM), on mIPSC frequency (50.2 ± 12.1%, n = 8, Fig. 
6.4C) was not reduced in the presence of the PKC antagonist, chelerythrine (1 
µM, 44.9 ± 7.3%, n = 6).  A cumulative probability curve from a representative 
neuron shows that 1 mM dBcAMP still shifts the curve to the left in the presence 
of 1 µM chelerythrine (Fig. 6.4D).  These results suggest that the PKC agonist-
induced increase in spontaneous GABA release is not dependent on activation of 
PKA, and the PKA agonist-induced increase in spontaneous GABA release is not 
dependent on activation of PKC. 
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DISCUSSION 
The PI-PLC antagonist, edelfosine, blocked ethanol from increasing 
spontaneous GABA release, which suggests that PLC contributes to ethanol-
enhanced spontaneous GABA release.  Edelfosine has varying effects on 
intracellular calcium levels based on the cell type, proliferation state, and the 
edelfosine concentration used (Lohmeyer and Workman, 1993; Bergmann et al., 
1994; Alonso et al., 1997; Jan et al., 1999).  A between cell comparison found no 
effect of edelfosine on spontaneous GABA release compared to neurons 
exposed to control conditions.  If there was a large increase in intracellular 
calcium after exposure to edelfosine, one would expect to see a large increase in 
spontaneous GABA release.  Additional experiments were attempted with the 
general PLC antagonist, U73122, but there was an overall increase in GABA 
release (data not shown), suggesting that there were effects occurring through a 
PLC-independent pathway.  Consistent with these data, PLC-independent effects 
have been reported for U73122 (Pulcinelli et al., 1998; Lockhart and McNicol, 
1999).  Based on this evidence, I conclude that PLCβ is necessary for ethanol-
enhanced spontaneous GABA release.  This conclusion is consistent with the 
IP3R data and internal calcium store data presented in Chapter 4. 
A general PKC antagonist and a PKCε specific antagonist inhibited 
ethanol-enhanced GABA release, which is similar to what is seen in the central 
nucleus of the amygdala (Bajo et al., 2008).  This interaction between ethanol 
and PKCε at the molecular level is consistent with what is seen behaviorally in 
PKCε null mice that are exposed to alcohol.  Specifically, these mice consume 
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less alcohol and are supersensitive to the behavioral effects of alcohol compared 
to wild-type controls (Hodge et al., 1999).  While the current results suggest that 
PKCε is necessary for ethanol-enhanced spontaneous GABA release, it does not 
suggest that PKCε is the only PKC isoform involved in this ethanol mechanism.  
PKCε is an atypical PKC isoform, which differ from typical PKC isoforms by not 
requiring calcium for activation (for review see Steinberg, 2008).  Typical PKC 
isoforms, which are the isoforms most likely to be activated by the PLCβ 
pathway, are also involved in generating the behavioral response to ethanol.  In 
contrast to the PKCε null mice, PKCγ null mice are less sensitive to the 
intoxicating effects of alcohol and consume more alcohol than wild-type mice 
(Harris et al., 1995; Bowers and Wehner, 2001).  PKCδ null mice are also less 
sensitive to the intoxicating effects of alcohol (Choi et al. 2008).  Therefore, 
multiple PKC isoforms contribute to the behavioral effects of alcohol and the 
isoforms can have opposite effects on alcohol-related behaviors.  Moreover, it is 
possible that multiple PKC isoforms play a role in ethanol-enhanced spontaneous 
GABA release.  
The PKC general antagonist had no effect on baseline spontaneous 
GABA release, while the PKCε specific antagonist increased spontaneous GABA 
release.  These results are consistent with a study conducted in the amygdala 
that used the same PKCε specific antagonist in addition to PKCε null mice (Bajo 
et al., 2008).   These results suggest that PKCε regulates the amount of GABA 
released from the presynaptic terminal.  Furthermore, because the PKC general 
antagonist had no effect on spontaneous GABA release, it is likely that another 
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PKC isoform increases the amount of GABA released to cancel out the inhibitory 
effect of PKCε.  These results are consistent with the opposing effects of the 
PKC isoforms on alcohol-related behaviors (see above). 
At the lower εV1-2 concentration, there was an increase and a decrease in 
mIPSC fast decay time and mIPSC amplitude, respectively.  The change in both 
mIPSC fast decay time and amplitude mostly likely reflects a change in the 
functioning of the postsynaptic GABAA receptors.  Consistent with this, there is 
evidence of PKCε regulating GABAA receptor sensitivity to ethanol through 
phosphorylation of the GABAA receptor γ2 subunit (Qi et al., 2007).  Interestingly, 
both of these effects on mIPSC properties are not present at a higher εV1-2 
concentration.  One explanation is that a nonspecific effect is occurring at the 
higher concentration, such as inhibition of another PKC isoform, that counteracts 
the PKCε effect on postsynaptic GABAA receptors.  It should be noted that the 
ethanol studies with εV1-2 were conducted at the lower concentration.  Overall, it 
appears that the PKC isoforms have different effects on GABAergic 
neurotransmission.   
Two PKC activators, PMA and SC9, both increased spontaneous GABA 
release, with PMA increasing spontaneous GABA release to a much higher 
extent.  PMA is a phorbol ester that binds to the C1 domain of PKC, while SC9 
binds to the C2 domain (Ito et al., 1986; Ono et al., 1989).  The C1 domain 
sequence is conserved in other proteins, which raises the possibility that PKC 
agonists acting at the C1 domain, such as PMA, are having nonspecific effects.  
For instance, the C1 domain is conserved in the Munc-13 protein, which has 
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effects on the neurotransmitter release machinery (Betz et al., 1998; Brose and 
Rosenmund, 2002; Kazanietz, 2002); moreover, phorbol esters modulate 
neurotransmitter release through both Munc-13 and PKC (Lou et al., 2008).  
Therefore, it is possible that PMA does not selectively activate PKC to affect 
spontaneous GABA release.  Because SC9 acts at the C2 domain, which is 
another domain conserved in a number of proteins (including one that plays a 
role in neurotransmitter release), additional studies will be needed to determine if 
this effect on spontaneous GABA release is PKC specific (Rizo and Sudhof, 
1998).  For example, one could determine if the PKC agonist effect on 
spontaneous GABA release can be inhibited by a general PKC antagonist.  
Interestingly, the effect of the PKCε antagonist on mIPSC frequency, fast decay 
time and amplitude goes in the same direction as the effect of the general PKC 
agonist on mIPSC frequency, fast decay time and amplitude.  Overall, the results 
from the PKC agonist and antagonist experiments suggest that PKC plays a role 
in the generation of spontaneous GABA release. 
Next I wanted to determine if there is overlap in the pathways involved in 
ethanol-enhanced spontaneous GABA release.  Cross-talk occurs between PKA 
and PKC at the GABAergic nucleus basalis of Meynert synapses (Kubota et al., 
2003); furthermore, there are ethanol effects that involve cross-talk between 
these protein kinases.  One mechanism involves ethanol increasing adenylate 
cyclase isoform 7 activity through a PKCδ-mediated mechanism, which leads to 
activation of PKA (Tabakoff et al., 2001).  Another example involves ethanol 
inducing PKCε translocation to the cytosol through a PKA-dependent mechanism 
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(Yao et al., 2008). Specifically, this translocation of PKCε is thought to involve 
PKA activation of PLCβ.  Therefore, it is tempting to speculate that the 
mechanism of ethanol-enhanced GABA release depends on cross-talk occurring 
between PKA and PKC.   
Experiments were designed to determine if cross-talk is occurring between 
PKA and PKC in this ethanol mechanism.  A required control for these 
experiments was to determine whether ethanol increases spontaneous GABA 
release in the presence of a PKC agonist or a PKA agonist.  Both agonists 
blocked the ability of ethanol to increase spontaneous GABA release; therefore, 
the cross-talk experiments were not conducted because the agonists were 
supposed to “rescue” the block induced by the antagonist.  However, these 
results imply that ethanol must induce a change in the activation state of the 
protein kinases to increase spontaneous GABA release and cannot simply 
interact with a downstream pathway that was activated by the protein kinase. 
As an alternative to the experiment described above, I tested if a PKC 
antagonist could block the effect of a PKA agonist (and vice versa) on 
spontaneous GABA release.  Neither antagonist was effective at blocking the 
effect of the opposite agonist, which suggests that cross-talk is not occurring 
between PKA and PKC to modulate GABA release at the interneuron-Purkinje 
cell synapse.   
 
 
 
105 
 
 
Figure 6.1.  Phospholipase C and protein kinase C antagonists prevented 
ethanol from increasing mIPSC frequency. A, edelfosine (10 µM), 
chelerythrine (1 µM), and εV1-2 (0.5 µM) prevented 100 mM ethanol from 
increasing mIPSC frequency compared to control (*, p<.05, one-way ANOVA, 
Dunnett’s post hoc test). B, a trace from a representative neuron demonstrating 
the effect of 100 mM ethanol on mIPSC frequency in the presence of edelfosine 
(10 µM). C, ethanol (50 and 100 mM) increased mIPSC frequency when 20 µM 
PKC(19-36) was in the pipette internal solution (PKC(19-36)int ; *, p<.05, one-way 
ANOVA, Dunnett’s post hoc test). D, a trace from a representative neuron 
showing the effect of 100 mM ethanol on mIPSC frequency when PKC(19-36) 
was included in the pipette internal solution. 
 
 
 
 
 
0
5
10
15
20
25
30
35
* *
*
Control:
100 mM EtOH
10 µM
Edelfosine
0.5 µM
εV1-2
1 µM
chelerythrine
+100 mM EtOH
%
 
Ch
a
n
ge
 
in
 
m
IP
SC
 
Fr
e
q
0
5
10
15
20
25
30
35
*
*
%
 
Ch
a
n
ge
 
in
 
m
IP
SC
 
Fr
e
q
Control:
20 µM PKC(19-36)int
20 µM PKC(19-36)int
+50 mM Ethanol
20 µM PKC(19-36)int
+100 mM Ethanol
10 µM Edelfosine+ 100 mM Ethanol
Control: 10 µM Edelfosine
Washout: 10 µM Edelfosine
20 µM PKC(19-36)int + 100 mM Ethanol
Control: 20 µM PKC(19-36)int
Washout: 20 µM PKC(19-36)int
A B
C D
20 pA
3 s
20 pA
3 s
106 
 
 
Figure 6.2.  Inhibition of PKC affected baseline mIPSC properties. A, the 
higher concentration of εV1-2 (5 µM) increased mIPSC frequency (*, p<.05, 
paired Student’s t test). B, there was a significant increase in mIPSC fast decay 
time (τ-fast) at 0.5 µM εV1-2 (*, p<.05, paired Student’s t test). C, there was an 
increase in mIPSC slow decay time (τ-slow) at 10 µM chelerythrine (chel; *, 
p<.05, paired Student’s t test). D, εV1-2 (0.5 µM) decreased mIPSC amplitude (*, 
p<.05, paired Student’s t test).  
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Figure 6.3.  Activation of PKC affected baseline mIPSC properties. A, all 
concentrations of the PKC agonists that were tested increased mIPSC frequency 
(*, p<.05, paired Student’s t test). B, there was a significant increase in mIPSC 
fast decay time (τ-fast) at 25 µM SC9 (*, p<.05, paired Student’s t test). C, no 
effect was seen on mIPSC slow decay time (τ-slow) with either of the PKC 
agonists. D, PMA (10 µM) decreased mIPSC amplitude (*, p<.05, paired 
Student’s t test).  
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Figure 6.4.  Activation of PKA and PKC was necessary for ethanol to 
increase mIPSC frequency and PKA and PKC were not dependent on each 
other to increase mIPSC frequency. A, dBcAMP (dB, 100 µM and 300 µM) and 
SC9 (25 µM) prevented 100 mM ethanol from increasing mIPSC frequency (*, 
p<.05, one-way ANOVA, Dunnett’s post hoc test). B, a trace from a 
representative neuron showing the effect of 100 mM ethanol on mIPSC 
frequency in the presence of dBcAMP. C, Rp-cAMP (25 µM) did not prevent SC9 
(25 µM) from increasing mIPSC frequency (*, p<.05, Student’s t test).  Likewise, 
chelerythrine (chel, 1 µM) did not prevent dBcAMP (1mM) from increasing 
mIPSC frequency (*, p<.05, Student’s t test). D, a cumulative frequency 
histogram from a representative neuron demonstrating the effect of dBcAMP on 
the interevent interval curve in the presence of chelerythrine. 
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Chapter VII: General Discussion 
 
The intoxicating effects of alcohol are partially mediated through 
modulation of the GABAergic system.  A person who is less sensitive to the 
intoxicating effects of alcohol is prone to developing alcoholism (Schuckit, 2009), 
so understanding the molecular mechanisms contributing to alcohol intoxication 
will further our understanding of this disease.  Within the past few years it was 
discovered that the GABAergic profile of ethanol consists of more than a direct 
ethanol interaction with the postsynaptic GABAA receptors and can involve 
activation of extrasynaptic GABAA receptors as well as an increase in GABA 
release from presynaptic terminals.  The current studies provided information 
regarding the mechanism responsible for the ethanol-induced increase in GABA 
release.      
With the use of whole-cell voltage clamp recordings, it was established 
that ethanol increases spontaneous and evoked GABA release at the 
interneuron-Purkinje cell synapse.  Activation of cannabinoid 1 receptors or 
GABAB receptors, both of which are Gαi-linked GPCRs, inhibits ethanol-
enhanced spontaneous GABA release. There was no tonic activation of the 
cannabinoid receptors, and while there was tonic activation of the GABAB 
receptors, inhibiting the GABAB receptors did not affect ethanol-enhanced 
spontaneous GABA release.  The ability of ethanol to increase spontaneous 
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GABA release is dependent on calcium release from internal stores, adenylate 
cyclase, PKA, PLC and PKC; moreover, these intracellular messengers act at the 
presynaptic terminal.  Influx of extracellular calcium into the neuron is not 
involved in this ethanol mechanism.  Because there are potential nonspecific 
effects that can occur with use of the IP3R antagonist, electron microcopy was 
used to show that IP3Rs are located in the presynaptic terminals at this synapse.  
It was also determined that both PKA and PKC contribute to the generation of 
spontaneous GABA release and cross-talk is not occurring between these two 
intracellular messengers.   
 
Is there a connection between the pathways?  
 The current results suggest that the mechanism of ethanol-enhanced 
spontaneous GABA release at the interneuron-Purkinje cell synapse involves 
activation of the Gαq-linked pathway, the Gαs-linked pathway and calcium release 
from internal stores.  The contribution of each is required for ethanol to increase 
spontaneous GABA release but no one pathway is necessarily sufficient.  In 
Chapter 6 I attempted to perform PKA/PKC cross-talk experiments, but this was 
unsuccessful because both the agonists and antagonists inhibit ethanol-
enhanced spontaneous GABA release.  However, the experiments provided 
useful information: the mechanism of ethanol-enhanced spontaneous release 
involves an increase in activated PKA and PKC.  Therefore, either ethanol is 
acting upstream to activate PKA and PKC or is activating PKA and PKC directly.  
If ethanol is acting upstream to activate PKA and PKC, two likely candidates are 
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adenylate cyclase and PLC, respectively, because data support the involvement 
of both in this ethanol mechanism.  I found that a PKA antagonist did not block 
the PKC agonist from increasing spontaneous GABA release, and vice versa, 
which suggests that the two protein kinases are not dependent on each other to 
increase spontaneous GABA release.  Therefore, while cross-talk could still 
occur in the mechanism of ethanol-enhanced spontaneous GABA release, it is 
not a necessity because both kinases are capable of independently increasing 
spontaneous GABA release.   
How does calcium release from internal stores fit into this mechanism?  I 
hypothesize that ethanol does not bind directly to the IP3R and RyR to increase 
spontaneous GABA release.  As mentioned previously, PKC has a binding site 
on the IP3R and PKA has binding sites on the IP3R and the RyR (Mignery et al., 
1990; Patterson et al., 2004; Sobie et al., 2006).  When either binds to its 
respective site, there is an increase in the amount of calcium released from the 
internal stores (Mignery et al., 1990; Bugrim, 1999; Bardo et al., 2006).  The link 
between calcium and PKC is well-established, and I provided evidence that the 
PKA effect on spontaneous GABA release is dependent on calcium (Chapter 5).  
Therefore, I propose that ethanol activates PKA and PKC and these two kinases 
phosphorylate the IP3Rs and RyRs to increase the amount of calcium released 
from the internal stores, which increases the amount of spontaneous GABA 
release.  This proposed mechanism does not limit the actions of PKA and PKC to 
the internal calcium stores and it is likely that both have other means of 
regulating spontaneous GABA release.  For instance, PKA and PKC have known 
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effects on the neurotransmitter release machinery (Trudeau et al., 1996; Chheda 
et al., 2001; Seino and Shibasaki, 2005; Lou et al., 2008).   
All the current ethanol experiments were conducted with the general 
protocol of inhibiting an intracellular messenger with the appropriate antagonist 
and determining if ethanol could increase spontaneous GABA release under 
these conditions.  For example, I demonstrated that BAPTA-AM and antagonists 
that inhibit calcium release from the internal stores block ethanol-enhanced 
spontaneous GABA release.  As a result of these data, I inferred that ethanol 
was increasing intracellular calcium to increase spontaneous GABA release.  
These experiments could be taken a step further by determining if ethanol 
directly increases calcium release in the presynaptic terminal with two-photon 
calcium imaging.  If I found that ethanol does increase calcium release from 
internal stores using this technique, it would be interesting to see if a PKA and 
PKC antagonist could block this ethanol effect.   This experiment would directly 
test the hypothesis that PKA and PKC are mediating the ethanol-induced 
increase in calcium release from internal stores.   
 
Yin and Yang: the ethanol effect on GABA and glutamate 
 During alcohol intoxication, ethanol increases GABA neurotransmission 
and decreases glutamate neurotransmission (see Chapter 1).   The present work 
and the work of others have provided evidence that ethanol can increase GABA 
release from the presynaptic terminal.  Moreover, ethanol can decrease 
glutamate release from the presynaptic terminal, although this effect is not as 
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well characterized.  In spinal motorneurons, ethanol inhibits both NMDA receptor-
mediated and non-NMDA receptor mediated spontaneous glutamate release, 
and within the same neuron increases spontaneous GABA release (Ziskind-
Conhaim et al., 2003).  Ethanol reduces glutamate neurotransmission at the 
crayfish neuromuscular junction by decreasing the release of glutamate-filled 
vesicles (Strawn and Cooper, 2002).  Ethanol inhibits NMDA receptor-mediated 
spontaneous and evoked glutamate release in the hippocampus but has no 
effect on non-NMDA receptor mediated spontaneous glutamate release 
(Hendricson et al., 2003; Hendricson et al., 2004).  There was no effect of 
ethanol on glutamate release onto the central nucleus of the amygdala neurons 
unless the animals had undergone chronic ethanol treatment (Roberto et al., 
2004).  There was no effect of ethanol on glutamate release onto cerebellar 
Purkinje cells (Carta et al., 2006; Belmeguenai et al., 2008).  Ethanol also had no 
effect on action potential-independent glutamate release in the VTA, but there 
was an increase in action potential-dependent glutamate release (Xiao et al., 
2009).  Therefore, current evidence supports that ethanol decreases glutamate 
release, but like the effect of ethanol on GABA release, it happens in a brain 
region-specific fashion.   
 
What mechanism is responsible for the different ethanol effect on GABA 
and glutamate release? 
That ethanol affects GABA and glutamate release in opposite directions 
poses a conundrum because internal calcium stores, the Gαq-linked pathway and 
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the Gαi/s-linked pathway modulate baseline GABA and glutamate release in the 
same manner (Malenka et al., 1986; Hopkins and Johnston, 1988; Weisskopf et 
al., 1994; Bouron, 1999; Hori et al., 1999; Emptage et al., 2001; Simkus and 
Stricker, 2002; Lee et al., 2008).  Therefore, ethanol cannot be activating the 
same intracellular messengers to increase and decrease GABA and glutamate 
release, respectively.   
It is possible that ethanol is acting through different intracellular 
messengers.  This seems unlikely since I found that a number of intracellular 
messengers are involved in ethanol-enhanced GABA release.  However, one 
possibility is extracellular calcium because influx of extracellular calcium does not 
play a role in ethanol-enhanced spontaneous GABA release (Chapter 4).  
Therefore, it is possible that influx of extracellular calcium into the neuron is 
necessary to generate spontaneous glutamate release and ethanol is preventing 
this influx to cause a decrease in glutamate release.  This is something that can 
be tested in the future in brain regions that show an ethanol-induced decrease in 
glutamate release.  
The other possibility is that ethanol is acting through the same intracellular 
messengers but is having an opposite effect on them.  Ethanol could be acting 
upstream of a particular messenger or activating the intracellular messenger 
directly.   There is evidence of an “ethanol-responsive domain” within adenylate 
cyclase (Yoshimura et al., 2006), but so far this is the only support for such a 
domain existing on an intracellular messenger.  If ethanol binds directly to the 
intracellular messengers to regulate GABA and glutamate
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need to differentiate between the intracellular messengers in the GABAergic and 
glutamatergic terminals as well as have an opposite effect on these messengers.  
To differentiate between terminals, ethanol would need some type of “sensor” to 
recognize if a certain terminal is GABAergic or glutamatergic, but there is no 
support for an “ethanol sensor” existing.  Another possibility is that the 
intracellular messenger isoforms are divided between the GABA and glutamate 
terminals.  While isoform expression can vary by brain region, there is no current 
evidence suggesting that the isoforms are divided between terminals.   
Even if the isoforms were divided between the terminals, ethanol would 
need to have an opposite effect on the isoforms to regulate spontaneous GABA 
release.  The most likely candidate is PKC because PKCε and PKCγ have 
opposing effects on alcohol-induced behaviors (Harris et al., 1995; Hodge et al., 
1999; Bowers and Wehner, 2001), and I provided data that suggest there are 
PKC-isoform specific effects on spontaneous GABA release (Chapter 6).  
Ethanol does have different effects on the adenylate cyclase isoforms, but the 
isoforms are either insensitive or activated by ethanol- there is no opposite effect 
on activation (Yoshimura and Tabakoff, 1995).  Therefore, because there is no 
current evidence suggesting that ethanol can differentiate between the two 
terminal types and because there is minimal evidence suggesting that 
intracellular messenger isoforms could account for this effect, it is unlikely that 
ethanol is activating the intracellular messengers directly to mediate the increase 
and decrease in GABA and glutamate release, respectively.  There is more 
116 
 
evidence supporting that ethanol acts upstream of the intracellular messengers, 
which is discussed in more detail below. 
 
The role of GPCRs in the ethanol effect on neurotransmitter release 
One hypothesis to explain the opposing role of ethanol on GABA and 
glutamate release is that activation of different presynaptic GPCRs mediates the 
ethanol effect at each terminal.  Activation of the Gαi and Gαs–linked GPCRs has 
opposing effects on the adenylate cyclase/PKA pathway, and activation of these 
GPCRs is necessary for ethanol to affect GABA and glutamate release in some 
brain regions.  For instance, activation of the CRF1 receptor, which is a Gαs-
linked GPCR, is necessary for ethanol to increase GABA release in the 
amygdala.  Interestingly, endocannabinoid release from the postsynaptic neuron, 
which activates the presynaptic Gαi-linked cannabinoid 1 receptors, is necessary 
for ethanol to decrease glutamate release in the hippocampus (Basavarajappa et 
al., 2008).  In the nucleus accumbens, activation of presynaptic GABAB receptors 
is necessary for ethanol to inhibit NMDA receptor-mediated glutamate 
neurotransmission (Steffensen et al., 2000).  These results provide examples of 
activation of a presynaptic Gαs-coupled GPCR being necessary for ethanol to 
increase GABA release and activation of a presynaptic Gαi-coupled GPCR being 
necessary for ethanol to decrease glutamate release.  Additionally, antagonists 
for the δ-opioid receptor and the GABAB receptor, both of which are Gαi-linked 
GPCRs, augment the ability of ethanol to increase GABA release in the 
amygdala and hippocampus (Ariwodola and Weiner, 2004; Zhu and Lovinger, 
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2006; Kang-Park et al., 2007).  Therefore, activation of Gαi-coupled GPCRs can 
attenuate the ethanol-induced increase in GABA release.    
Interestingly, Xiao and Ye (2008) found that ethanol decreases GABA 
release in the VTA, but in the presence of a µ-opioid receptor agonist, which 
activates a Gαi-coupled GPCR, ethanol increases GABA release.  The authors 
suggest that the µ-opioid receptor agonist “silences” a population of GABAergic 
neurons that decrease GABA release in the presence of ethanol, which allows for 
a different population of GABAergic neurons- one that increases GABA release 
in the presence of ethanol- to dominate.  This study is in contrast to other studies 
in the VTA that found that ethanol increases GABA release in the absence of a µ-
opioid receptor agonist (Melis et al., 2002; Thiele et al., 2008).  Xiao and 
colleagues also found that ethanol increases glutamate release in the VTA, and 
this mechanism is dependent on activation of the dopamine 1 receptors, which 
are Gαs-linked GPCRs (Xiao et al., 2009).  Overall, these results suggest that 
activation of Gαi-linked GPCRs does not always selectively decrease glutamate 
release and activation of Gαs-linked GPCRs does not always selectively increase 
GABA release, at least in the VTA.  The data of Xiao and colleagues are the only 
evidence of ethanol decreasing and increasing GABA and glutamate release, 
respectively, in the brain.  While it is entirely possible that this effect is seen in 
other brain regions, more evidence will be needed to support that this effect is 
extended to other regions of the brain. Regardless, these data provide further 
support for the important role that GPCRs play in the effect of ethanol on 
neurotransmitter release.   
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So how are these GPCRs activated by ethanol?  Ethanol does not 
nonspecifically increase activation of every GPCR throughout the brain.  For 
example, both µ-opioid receptor null mice and a µ-opioid receptor antagonist 
increase baseline GABA release but have no effect on ethanol-enhanced GABA 
release in the central nucleus of the amygdala (Kang-Park et al., 2009).  
Additionally, there is tonic activation of GABAB receptors in the cerebellum and 
VTA, but inhibiting these GABAB receptors has no effect on ethanol-enhanced 
spontaneous GABA release (Chapter 5; Thiele et al., 2008).  Because ethanol 
does not always activate a given presynaptic GPCR, even when activation of the 
GPCR affects GABA release, I find it unlikely that ethanol is binding to an 
“ethanol binding site” on the GPCRs.  This concept was suggested previously for 
the GABAB receptors because of differences in the activation of presynaptic and 
postsynaptic GABAB receptors by ethanol (Ariwodola and Weiner, 2004). 
 Another possibility is that ethanol increases the concentration of the 
endogenous agonist that activates the GPCR.  This would explain why there is 
tonic activation of a GPCR at a presynaptic terminal, which provides evidence 
that the particular GPCR is there and can affect neurotransmitter release, while 
there is no contribution of this same GPCR to the effect of ethanol on 
neurotransmitter release: ethanol does not change the amount of endogenous 
agonist that reaches the presynaptic GPCR.  Therefore, despite the fact that a 
presynaptic GPCR is present, it is not necessarily involved in this ethanol 
mechanism.  However, this hypothesis fails to explain how ethanol increases 
spontaneous GABA release in the mechanically dissociated neuron preparation 
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(Zhu and Lovinger, 2006; Fig. 3.2).  Potential explanations include ethanol 
increasing release of a retrograde messenger or activating non-GABAergic 
presynaptic terminals that are still attached to the Purkinje cell in the 
mechanically dissociated neuron preparation.  Both of these explanations seem 
unlikely and therefore weaken the hypothesis that ethanol is increasing the 
concentration of an endogenous agonist to activate the GPCRs.    More work will 
be necessary to determine the interaction between ethanol and the GPCRs that 
would be consistent with what is known about the ethanol effect on 
neurotransmitter release. 
 
The role of calcium in the ethanol effect on neurotransmitter release  
In addition to the GPCRs, calcium signaling could also play an important 
role in determining if ethanol is going to affect neurotransmitter release at a 
particular synapse.  In normal external calcium concentrations, a cannabinoid 
agonist decreases spontaneous GABA release at the interneuron-Purkinje cell 
synapse and has no effect on spontaneous glutamate release at the parallel 
fiber-Purkinje cell synapse (Yamasaki et al., 2006).  However, if the calcium 
concentration in the extracellular solution is increased, the cannabinoid agonist 
decreases glutamate release at the parallel fiber-Purkinje cell synapse.  The 
authors conclude that cannabinoids selectively interact with “calcium-enhanced” 
neurotransmitter release, and at normal external calcium concentrations there is 
calcium-enhanced spontaneous GABA release but not calcium-enhanced 
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spontaneous glutamate release onto Purkinje cells (Carter et al., 2002; Yamasaki 
et al., 2006).   
Yamasaki and colleagues found that this effect is not limited to 
cannabinoid receptors- activation of GABAB receptors and group 3 mGluRs have 
no effect on spontaneous glutamate release onto Purkinje cells in normal 
external calcium concentrations, but when the calcium concentration in the 
extracellular solution is increased, activation of GABAB receptors and group 3 
mGluRs decreases glutamate release.  All of these receptors are Gαi-linked 
GPCRs, which provides an additional link between this pathway and calcium.  
Consistent with these data, I provided evidence for PKA being involved in the 
cannabinoid-mediated decrease in spontaneous GABA release, and the PKA 
antagonist-induced decrease in spontaneous GABA release occurred through a 
calcium-dependent mechanism (Chapter 5).   
A likely source for these calcium-enhanced events is calcium release from 
internal stores because inhibition of calcium release from internal stores 
suppresses the cannabinoid effect on spontaneous GABA release at the 
interneuron-Purkinje cell synapse (Yamasaki et al., 2006; Chapter 5).  I provided 
evidence that the ability of ethanol to increase spontaneous GABA release at the 
interneuron-Purkinje cell synapse is dependent on calcium release from internal 
stores (Chapter 4).  Calcium release from internal stores does not affect 
glutamate release at the parallel fiber-Purkinje cell synapse (Carter et al., 2002), 
and at the parallel fiber-Purkinje cell synapse ethanol has no effect on glutamate 
release (Belmeguenai et al., 2008).  Therefore, similar to the cannabinoids, 
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ethanol could selectively alter “calcium-enhanced” neurotransmitter release that 
is due to calcium release from the internal stores.   
This concept of “calcium-enhanced” neurotransmitter release works to 
explain how ethanol modulates neurotransmitter release onto Purkinje cells, and 
more studies will be needed before this theory can be applied to the whole brain.  
An interesting future experiment would be to see if the presence of a high 
calcium extracellular solution could reverse the lack of ethanol effect on mIPSC 
frequency in the cortex, thalamus and lateral septum (Criswell et al., 2008; Jia et 
al., 2008).  Additionally, one could investigate if the presence of a high calcium 
extracellular solution could reverse the reported lack of ethanol effect on 
glutamate release in the amygdala and cerebellum (Roberto et al., 2004; Carta et 
al., 2006; Belmeguenai et al., 2008).  If the experiments are successful, one 
could determine if blocking calcium release from the internal stores in the 
presence of the high calcium extracellular solution could revert ethanol back to 
having no effect on release. 
 
The big picture: the interneuron-Purkinje cell synapse and beyond 
While I have focused on the effect of ethanol at the presynaptic terminal, 
one should keep in mind that this change in neurotransmitter release affects the 
activation of postsynaptic ionotropic and metabotropic receptors.  A change in 
the amount of neurotransmitter binding to the ionotropic receptors can depolarize 
or hyperpolarize the postsynaptic neuron, which affects the excitability of the cell.  
A change in the amount of neurotransmitter binding to the metabotropic 
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receptors can have a number of effects on the neuron, which are generally 
longer lasting than the effects induced by the ionotropic receptors.  When ethanol 
increases the amount of GABA released from the basket and stellate cells, there 
is an increase in activation of the Purkinje cell GABAA receptors.  The increase in 
chloride flux would hyperpolarize the Purkinje cell, and this is consistent with the 
ethanol-induced decrease in Purkinje cell firing (Siggins and French, 1979; 
Sorensen et al., 1980; George and Chu, 1984).  Decreased Purkinje cell firing 
leads to motor incoordination, which also occurs during alcohol intoxication 
(Servais et al., 2005; Levin et al., 2006).   
Because the goal of the current work was to determine the intracellular 
messengers involved in ethanol-enhanced GABA release, analysis of action 
potential-independent release was ideal since there is a direct readout for 
changes at the presynaptic terminal.  However, neurotransmission involves 
action potential-dependent release, so conducting evoked neurotransmitter 
release studies will be necessary when trying to figure out the effect of ethanol 
throughout the brain.  Additionally, experiments should be done to explore the 
contribution of presynaptic GPCRs to the ethanol effect on neurotransmitter 
release in different brain regions.  To start, studies should be undertaken to 
determine what GPCR(s) is/are activated at the interneuron-Purkinje cell 
synapse to allow ethanol to increase GABA release.  It will likely involve 
activation of a Gαs- or Gαq-linked GPCR because activation of either receptor is 
consistent with an increase in neurotransmitter release.  
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Most importantly, it should be determined if chronic alcohol treatment 
affects the ethanol-induced increase in GABA release.  For example, if rats were 
made alcohol-dependent before the electrophysiology experiments, would 
ethanol increase GABA release to the same extent?  If so, is it occurring through 
the same mechanism?  One could also determine if there is an effect on baseline 
GABA release after chronic ethanol treatment.  Comparing these results to the 
results from alcohol naïve rats will give us an idea of the neuroadaptations that 
are occurring during chronic alcohol use, which would contribute to our 
understanding of the development of alcoholism.  
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